

10/719,896

10/719,896

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 6 NOV 10 CA/CAPLUS F-Term thesaurus enhanced  
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version  
8.01c now available  
NEWS 8 NOV 20 CA/CAPLUS to MARPAT accession number crossover limit increased  
to 50,000  
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and  
functionality  
NEWS 13 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced  
with preparation role  
NEWS 14 DEC 18 CA/CAPLUS patent kind codes updated  
NEWS 15 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased  
to 50,000  
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 17 DEC 27 CA/CAPLUS enhanced with more pre-1907 records  
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 19 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded  
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 22 JAN 22 CA/CAPLUS updated with revised CAS roles  
NEWS 23 JAN 22 CA/CAPLUS enhanced with patent applications from India  
NEWS 24 JAN 29 PHAR reloaded with new search and display fields  
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 26 FEB 13 CASREACT coverage to be extended  
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 29 Feb 23 KOREAPAT enhanced with IPC 8 features and functionality  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

10/719,896

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:27:20 ON 26 FEB 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:27:28 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10719896RCE6.str

10/719,896



chain nodes :  
7 8 9 22 23 24 25 26 27 31 32 33 35 36 37 38 39 40 45  
ring nodes :  
1 2 3 4 5 6 10 11 12 13 14 15  
chain bonds :  
1-22 3-45 4-31 5-23 7-8 7-9 24-26 25-27 32-33 35-36 36-37 37-38 39-40  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15  
exact/norm bonds :  
1-22 3-45 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26  
25-27 32-33 35-36 36-37 37-38 39-40  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,CH2,NH,[\*1]

G2:[\*2],[\*3]

G3:H,OH,COOH,NH2,X,Ak,[\*4],[\*5]

G4:C,O,S,N

G5:cy,[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 22:CLASS 23:Atom 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS  
38:Atom 39:Atom 40:CLASS 45:CLASS

10/719,896

Generic attributes :

23:

Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 11:27:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 19007 TO ITERATE

10.5% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 371886 TO 388394  
PROJECTED ANSWERS: 391 TO 1129

L2 4 SEA SSS SAM L1

=> d scan




10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI)

MF C19 H20 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- $\alpha,\alpha$ -dimethyl-  
(9CI)

MF C27 H32 Cl F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI)


MF C30 H39 N7 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-  
[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
MF C26 H28 F4 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/719,896

=> s l1 sss ful

FULL SEARCH INITIATED 11:28:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 381506 TO ITERATE

100.0% PROCESSED 381506 ITERATIONS

1080 ANSWERS

SEARCH TIME: 00.00.05

L3 1080 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 11:28:30 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Feb 2007 VOL 146 ISS 10

FILE LAST UPDATED: 25 Feb 2007 (20070225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 63 L3

=> d l4 1-63 bib hitstr

10/719,896

L4 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:886413 CAPLUS

DN 145:293108

TI Preparation of methylenedihydrazotriazinediamine derivatives and related analogs as inhibitors of mTOR

IN Hummersone, Marc Geoffrey; Gomez, Sylvie; Menear, Keith Allan; Cockcroft, Xiao-Ling Fan; Smith, Graeme Cameron Murray

PA Kudos Pharmaceuticals Limited, UK

SO PCT Int. Appl., 80pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006090167	A2	20060831	WO 2006-GB668	20060224
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006199804	A1	20060907	US 2006-361599	20060224
PRAI	GB 2005-3962	A	20050225		
	US 2005-656193P	P	20050225		

OS MARPAT 145:293108

IT 908141-65-1P 908141-66-2P 908141-67-3P

908141-68-4P 908141-69-5P 908141-70-8P


908141-71-9P 908141-72-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of methylenedihydrazotriazinediamine derivs. and related analogs as inhibitors of mTOR)

RN 908141-65-1 CAPLUS


CN Phenol, 4-[5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-2-furanyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 908141-66-2 CAPLUS


CN Benzenemethanol, 5-[5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-2-furanyl]-2-methoxy- (9CI) (CA INDEX NAME)

10/719,896




RN 908141-67-3 CAPLUS

CN Morpholine, 4,4'-[6-[5-(4-pyridinyl)-2-furanyl]-2,4-pyrimidinediyl]bis-  
(9CI) (CA INDEX NAME)




RN 908141-68-4 CAPLUS

CN Benzenemethanol, 3-[5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-2-furanyl]-  
(9CI) (CA INDEX NAME)



RN 908141-69-5 CAPLUS


CN Benzenemethanol, 4-[5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-2-furanyl]-  
(9CI) (CA INDEX NAME)



10/719,896


RN 908141-70-8 CAPLUS

CN Phenol, 3-[5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 908141-71-9 CAPLUS

CN Phenol, 4-[5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 908141-72-0 CAPLUS

CN Morpholine, 4,4'-[6-[5-(2-fluorophenyl)-2-furanyl]-2,4-pyrimidinediyl]bis- (9CI) (CA INDEX NAME)



IT 908141-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of methylenedihydropyrimidinotriazinediamine derivs. and related analogs as inhibitors of mTOR)

RN 908141-99-1 CAPLUS

CN Morpholine, 4,4'-[6-(5-bromo-2-furanyl)-2,4-pyrimidinediyl]bis- (9CI) (CA INDEX NAME)



10/719,896



10/719,896

L4 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:796732 CAPLUS

DN 145:211069

TI Preparation of phenyl-substituted pyrimidines as kinase inhibitors for treating an inflammatory disorder and/or cancer

IN Wrobelski, Stephen T.; Lin, Shuqun; Leftheris, Katerina; He, Liqi; Seitz, Steven, P.; Lin, Tai-An; Vaccaro, Wayne

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 216pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084017	A2	20060810	WO 2006-US3659	20060202
	WO 2006084017	A3	20061214		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006178388	A1	20060810	US 2006-344881	20060201
PRAI	US 2005-650077P	P	20050204		
	US 2006-344881	A	20060201		
OS	MARPAT 145:211069				
IT	905296-10-8P 905296-20-0P 905296-30-2P 905296-50-6P 905296-78-8P 905299-30-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of phenyl-substituted pyrimidines as p38 kinase and LIM kinases inhibitors for treating an inflammatory disorder and cancer)				
RN	905296-10-8 CAPLUS				
CN	2-Thiazolamine, 5-[6-(2-chlorophenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)				



RN 905296-20-0 CAPLUS


10/719,896

CN 2-Thiazolamine, 5-[6-(2-chlorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 905296-30-2 CAPLUS

CN 2-Thiazolamine, 5-[6-(2-chloro-4-fluorophenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 905296-50-6 CAPLUS


CN 2-Thiazolamine, 5-[6-(2-chlorophenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 905296-78-8 CAPLUS


CN 2-Thiazolamine, 5-[6-(2-chlorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/719,896



RN 905299-30-1 CAPLUS

CN 2-Thiazolamine, 5-[6-[2,6-dimethyl-4-(phenylmethoxy)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:734267 CAPLUS  
DN 145:188896  
TI Preparation of heteroaryl substituted piperazinyl-pyridine analogues as  
VR1 modulators  
IN Blum, Charles A.  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006078992	A2	20060727	WO 2006-US2194	20060119
	WO 2006078992	A3	20060928		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRAI US 2005-645496P P 20050119

OS MARPAT 145:188896

IT 902770-86-9P 902770-87-0P 902770-88-1P


902770-89-2P 902770-90-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of heteroaryl substituted piperazinylpyridine analogs as VR1  
modulators for treating diseases associated with pathol. receptor  
activation)

RN 902770-86-9 CAPLUS


CN Pyrimidine, 4-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-(1H-  
tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 902770-87-0 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[4-(1-methyl-1H-imidazol-2-yl)-1-  
piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-, monohydrochloride (9CI) (CA  
INDEX NAME)


10/719,896



● HCl


RN 902770-88-1 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[4-(1-methyl-1H-imidazol-2-yl)-1-piperidinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 902770-89-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(4-chloro-1,2,5-thiadiazol-3-yl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 902770-90-5 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(1-methyl-1H-imidazol-2-yl)-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/719,896



● HCl


IT 902770-92-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl substituted piperazinylpyridine analogs as VR1 modulators for treating diseases associated with pathol. receptor activation)

RN 902770-92-7 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[4-(1H-imidazol-2-yl)-1-piperidinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:655968 CAPLUS  
DN 145:124594  
TI Preparation of pyrimidine-pyridine substituted biaryl analogs and their  
inhibition of VR1 type Capsaicin receptors  
IN Blum, Charles A.; Chenard, Bertrand L.; Hodgetts, Kevin J.; Zheng,  
Xiaozhang  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 69 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006071538	A2	20060706	WO 2005-US45306	20051213
	WO 2006071538	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRAI US 2004-635837P P 20041213

OS MARPAT 145:124594


IT 896742-07-7P 896742-08-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrimidine-pyridine substituted biaryl analogs and their  
inhibition of VR-1 type Capsaicin receptors)

RN 896742-07-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[6-(4-fluorophenyl)-2-(2-methyl-1-  
pyrrolidinyl)-4-pyrimidinyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX  
NAME)




RN 896742-08-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[6-(4-fluorophenyl)-2-(2-methyl-1-  
pyrrolidinyl)-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



10/719,896




IT 896742-05-5P 896742-09-9P 896742-10-2P  
896742-16-8P 896742-17-9P 896742-52-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of pyrimidine-pyridine substituted biaryl analogs and their  
inhibition of VR-1 type Capsaicin receptors)


RN 896742-05-5 CAPLUS

CN 4-Piperidinol, 1-[5-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-  
pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 896742-09-9 CAPLUS


CN 4-Piperidinecarboxamide, 1-[5-[6-(4-fluorophenyl)-2-(2-methyl-1-  
pyrrolidinyl)-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 896742-10-2 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[3'-(trifluoromethyl)[2,2'-  
bipyridin]-5-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 896742-16-8 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-(3'-methyl[2,2'-bipyridin]-5-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 896742-17-9 CAPLUS


CN 4-Piperidinemethanol, 1-[5-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 896742-52-2 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




IT 896742-06-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine-pyridine substituted biaryl analogs and their inhibition of VR-1 type Capsaicin receptors)

RN 896742-06-6 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-(6-fluoro-3-pyridinyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 5 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:601674 CAPLUS  
DN 145:62918  
TI Preparation of pyridinylpiperazinylpyrimidines for use in treatment of  
diseases or disorders associated with capsaicin receptor  
IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Chenard, Bertrand L.; Zheng,  
Xiaozhang  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065872	A1	20060622	WO 2005-US45184	20051213
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-635822P P 20041213

OS MARPAT 145:62918


IT 891830-66-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinylpiperazinylpyrimidines for use in treatment of diseases or disorders associated with capsaicin receptor)

RN 891830-66-3 CAPLUS

CN 1H-Indole, 5-fluoro-2,3-dihydro-1-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:343626 CAPLUS

DN 144:382034

TI Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of a VR1 antagonist

IN Cai, Dongwei; Jones, A. Brian

PA Merck Sharp & Dohme Limited, UK; Merck & Co., Inc.

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006038041	A1	20060413	WO 2005-GB50172	20051004
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-617134P P 20041008

OS MARPAT 144:382034

IT 882686-07-9 882686-08-0 882686-14-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of VR1 antagonist)


RN 882686-07-9 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-2-(2-methyl-1-pyrrolidinyl)-6-(7-quinolinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 852062-74-9

CMF C25 H23 F3 N6




10/719,896

CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882686-08-0 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-2-(4-morpholinyl)-6-(7-quinolinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 852062-75-0

CMF C24 H21 F3 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882686-14-8 CAPLUS


CN 4-Pyrimidinamine, 2-(4-morpholinyl)-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 852062-82-9

CMF C24 H20 F3 N5 O


10/719,896



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:301346 CAPLUS

DN 144:350708

TI Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases

IN Kalleda, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak

PA Reddy US Therapeutics, Inc., USA

SO PCT Int. Appl., 336 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034473	A2	20060330	WO 2005-US34243	20050923
	WO 2006034473	A3	20061214		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006084644	A1	20060420	US 2005-234257	20050923
	US 2006084645	A1	20060420	US 2005-234695	20050923
PRAI	US 2004-612374P	P	20040923		

OS MARPAT 144:350708


IT 881193-44-8P 881194-15-6P 881194-22-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 881193-44-8 CAPLUS

CN 4-Pyrimidinamine, 2-(4-morpholinyl)-6-phenyl-N-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 881194-15-6 CAPLUS

CN Ethanone, 1-[3-[2-(4-morpholinyl)-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-(9CI) (CA INDEX NAME)




10/719,896



RN 881194-22-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-[(3-chloro-4-hydroxyphenyl)amino]-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:232088 CAPLUS

DN 144:312100

TI Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands

IN Norman, Mark H.; Pettus, Liping H.; Wang, Xianghong; Zhu, Jiawang

PA USA

SO U.S. Pat. Appl. Publ., 96 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006058308	A1	20060316	US 2005-226844	20050913
	WO 2006031852	A1	20060323	WO 2005-US32660	20050913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-609718P P 20040913


OS MARPAT 144:312100

IT 879598-51-3P 879604-69-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands)

RN 879598-51-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[[2-(acetylamino)-4-benzothiazolyl]oxy]-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 879604-69-0 CAPLUS

CN 2(1H)-Quinoxalinone, 3-amino-5-[[2-(1-piperazinyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)

10/719,896




IT 879596-23-3P 879598-58-0P 879598-59-1P  
879598-66-0P 879598-67-1P 879598-86-4P  
879599-22-1P 879599-56-1P 879600-63-2P  
879601-96-4P 879602-02-5P 879602-07-0P  
879604-74-7P 879604-77-0P 879606-77-6P  
879606-82-3P 879606-87-8P 879606-92-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of substituted pyridines and pyrimidines as vanilloid receptor  
ligands)

RN 879596-23-3 CAPLUS


CN 4-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-(1,1-  
dimethylethyl)phenyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 879598-58-0 CAPLUS

CN Acetamide, N-[4-[[2-(1-piperazinyl)-6-[4-(trifluoromethyl)phenyl]-4-  
pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 879598-59-1 CAPLUS

CN Acetamide, N-[4-[[2-(1-piperazinyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 879598-58-0


CMF C24 H21 F3 N6 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 879598-66-0 CAPLUS

CN Acetamide, N-[4-[[2-[4-(2-methylpropyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 879598-67-1 CAPLUS

CN Acetamide, N-[4-[[2-[4-(2-methylpropyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 879598-66-0


CMF C28 H29 F3 N6 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 879598-86-4 CAPLUS

CN Acetamide, N-[4-[[2-(3-hydroxy-1-piperidinyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)


10/719,896



RN 879599-22-1 CAPLUS

CN Acetamide, N-[4-[[2-[4-[(1R)-1-(4-fluorophenyl)ethyl]-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 879599-56-1 CAPLUS


CN Acetamide, N-[4-[[2-[3-(diethylamino)-1-pyrrolidinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 879600-63-2 CAPLUS

CN Acetamide, N-[4-[[2-(3-methyl-1-piperazinyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 879601-96-4 CAPLUS


CN Acetamide, N-[4-[[2-[4-(1-methylethyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 879602-02-5 CAPLUS


CN Acetamide, N-[4-[[2-[3-methyl-4-(2-methylpropyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 879602-07-0 CAPLUS

CN    Acetamide, N-[4-[[2-[3-methyl-4-(1-methylethyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI)    (CA INDEX NAME)



RN 879604-74-7 CAPLUS

CN 2(1H)-Quinoxalinone, 3-amino-5-[[2-[4-(cyclopropylmethyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 879604-77-0 CAPLUS

CN 2(1H)-Quinoxalinone, 3-amino-5-[[2-[4-(2-methylpropyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




10/719,896



RN 879606-77-6 CAPLUS

CN Acetamide, N-[4-[[2-[(3R)-3-methyl-4-(2-methylpropyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 879606-82-3 CAPLUS

CN Acetamide, N-[4-[[2-[(3R)-3-methyl-4-(1-methylethyl)-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 879606-87-8 CAPLUS

CN Acetamide, N-[4-[[2-[(3S)-3-hydroxy-1-piperidinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 879606-92-5 CAPLUS

CN Acetamide, N-[4-[[2-[(3S)-3-methyl-1-piperazinyl]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/719,896



10/719,896

L4 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:211690 CAPLUS

DN 144:292781

TI Preparation of substituted biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators

IN Blum, Charles A.; Briemann, Harry; Chenard, Bertrand L.; Zheng, Xiaozhang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 216 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006026135	A2	20060309	WO 2005-US28969	20050813
	WO 2006026135	A3	20060615		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006122394	A1	20060608	US 2005-204202	20050813
PRAI	US 2004-601721P	P	20040813		
	US 2005-641796P	P	20050105		

OS MARPAT 144:292781


IT 878809-45-1P, [5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methanol  
878809-58-6P 878809-67-7P, 4-(3-Chloro-4-fluorophenyl)-6-[4-(3-methyl-5-nitropyridin-2-yl)piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878809-90-6P 878810-01-6P  
878810-13-0P 878810-15-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of biaryl piperazinyl-pyridine analogs as type VR1 capsaicin receptor modulators)

RN 878809-45-1 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878809-58-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-

10/719,896


pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878809-67-7 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-methyl-5-nitro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 878809-90-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methylpyridin-2-yl]piperazinyl]-3-methyl-1-piperazinyl]-5-methylpyridine-2-carboxylic acid (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-01-6 CAPLUS

CN Pyrazinecarboxylic acid, 6-chloro-5-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878810-13-0 CAPLUS

CN 3-Pyridineethanamine, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878810-15-2 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 833472-70-1P, 2-[4-[6-(3-Chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyrimidine-5-carbonitrile 878809-39-3P, [5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]acetic acid 878809-48-4P, 5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878809-56-4P, [[5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methyl]dimethylamine 878809-61-1P 878809-62-2P 878809-64-4P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878809-65-5P, [2-[6-[4-[6-(3-Chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]oxy]ethyl]dimethylamine 878809-69-9P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(pyridin-4-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid ethyl ester 878809-75-7P, 6-[4-[6-(2-Isopropylpyridin-4-yl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinic acid ethyl ester 878809-84-8P 878809-92-8P 878809-96-2P 878810-07-2P

878810-18-5P 878810-20-9P, 2-[4-[6-(3-Chloro-4-fluorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid ethyl ester 878810-21-0P, 2-[4-[6-(3-Chloro-4-fluorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinamide 878810-22-1P, 2-[4-[6-(3-Chloro-4-fluorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878810-23-2P, 4-[4-(3-Chloro-4-fluorophenyl)-6-[4-(3-nitropyridin-2-yl)piperazin-1-yl]pyrimidin-2-yl]morpholine 878810-24-3P, 3-Chloro-2-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]isonicotinic acid 878810-25-4P 878810-26-5P 878810-27-6P, [5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methanol 878810-28-7P, [[5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methyl]methylamine 878810-29-8P, [[5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methyl]amine 878810-30-1P 878810-31-2P, 5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinamide 878810-32-3P, [5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-propylpiperazin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methanol 878810-33-4P, 5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-propylpiperazin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878810-34-5P 878810-35-6P, [[5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methyl]dimethylamine 878810-36-7P, 5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid methyl ester 878810-37-8P, 5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878810-38-9P, 4-(3-Chloro-4-fluorophenyl)-6-[4-(6-methoxy-3-nitropyridin-2-yl)piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878810-39-0P, 5-Chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-propylpiperazin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid ethyl ester 878810-40-3P 878810-41-4P 878810-42-5P 878810-43-6P 878810-44-7P 878810-45-8P 878810-46-9P 878810-47-0P 878810-48-1P 878810-49-2P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinic acid 878810-50-5P, 5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinamide 878810-51-6P 878810-52-7P 878810-53-8P 878810-54-9P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878810-55-0P 878810-56-1P 878810-57-2P 878810-58-3P 878810-59-4P 878810-60-7P 878810-61-8P 878810-62-9P 878810-63-0P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-phenylpyrimidin-4-yl]piperazin-1-yl]nicotinic acid ethyl ester 878810-64-1P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(m-tolyl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid ethyl ester 878810-65-2P 878810-66-3P 878810-67-4P 878810-68-5P 878810-70-9P 878810-71-0P 878810-72-1P 878810-73-2P 878810-75-4P 878810-76-5P 878810-77-6P 878810-78-7P, [5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-phenylpyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methanol 878810-79-8P, [5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(m-tolyl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methanol 878810-80-1P, [5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(pyridin-4-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]methanol 878810-81-2P, [6-[4-[6-(2-Isopropylpyridin-4-yl)-2-(2-



methylpyrrolidin-1-yl]pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]methanol 878810-82-3P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-phenylpyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878810-83-4P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(m-tolyl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878810-84-5P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(pyridin-4-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid 878810-85-6P, 6-[4-[6-(2-Isopropylpyridin-4-yl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinic acid 878810-86-7P 878810-88-9P 878810-93-6P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-phenylpyrimidin-4-yl]piperazin-1-yl]nicotinamide 878810-94-7P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(m-tolyl)pyrimidin-4-yl]piperazin-1-yl]nicotinamide 878810-95-8P, 5-Methyl-6-[4-[2-(2-methylpyrrolidin-1-yl)-6-(pyridin-4-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinamide 878810-96-9P, 6-[4-[6-(2-Isopropylpyridin-4-yl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878810-97-0P 878810-98-1P 878810-99-2P 878811-00-8P 878811-01-9P 878811-02-0P 878811-03-1P 878811-04-2P 878811-05-3P 878811-06-4P 878811-07-5P 878811-08-6P 878811-09-7P, N-Cyclopropyl-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-10-0P, N-Cyclobutyl-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-11-1P, N-Cyclopentyl-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-12-2P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-(2-methoxyethyl)-5-methylnicotinamide 878811-13-3P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-(3-methoxypropyl)-5-methylnicotinamide 878811-14-4P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methyl-N-[(tetrahydrofuran-2-yl)methyl]nicotinamide 878811-15-5P, N-(3-Ethoxypropyl)-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-16-6P, N-Benzyl-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-17-7P, N-(4-Fluorobenzyl)-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-18-8P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-(4-methoxybenzyl)-5-methylnicotinamide 878811-19-9P, N-[3-(Dimethylamino)propyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-20-2P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-(2-methoxy-1-methylethyl)-5-methylnicotinamide 878811-21-3P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methyl-N-[(2-thienyl)methyl]nicotinamide 878811-22-4P, N-(2-Ethoxyethyl)-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinamide 878811-23-5P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methyl-N-(2,2,2-trifluoroethyl)nicotinamide 878811-24-6P, N-Benzyl-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-methyl-5-methylnicotinamide 878811-25-7P, 4-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)-6-[4-[3-methyl-5-[(pyrrolidin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]pyrimidine 878811-26-8P, 4-(4-Fluorophenyl)-6-[4-[3-methyl-5-[(piperidin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-27-9P, 4-[[6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]carbonyl]morpholine

878811-28-0P, 4-(4-Fluorophenyl)-6-[4-[3-methyl-5-[(4-methylpiperidin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-29-1P, 1-[[6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]carbonyl]azepane 878811-30-4P, 4-[[6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]carbonyl]thiomorpholine 878811-31-5P, 4-(4-Fluorophenyl)-6-[4-[3-methyl-5-[(2-methylpiperidin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-32-6P, N-Cyclohexyl-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-methyl-5-methylnicotinamide 878811-33-7P, 4-(4-Fluorophenyl)-6-[4-[3-methyl-5-[(4-phenylpiperidin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-34-8P, 4-(4-Fluorophenyl)-6-[4-[3-methyl-5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-35-9P, 4-(4-Fluorophenyl)-6-[4-[5-[[4-(2-methoxyethyl)piperazin-1-yl]carbonyl]-3-methylpyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-36-0P, 4-[4-[5-[(4-Cyclopentylpiperazin-1-yl)carbonyl]-3-methylpyridin-2-yl]piperazin-1-yl]-6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-37-1P, 4-[4-[5-[(4-Acetyl)piperazin-1-yl]carbonyl]-3-methylpyridin-2-yl]piperazin-1-yl]-6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-38-2P, 4-(4-Fluorophenyl)-6-[4-[3-methyl-5-[(2-methylpyrrolidin-1-yl)carbonyl]pyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-39-3P, N-[2-(Dimethylamino)ethyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-methyl-5-methylnicotinamide 878811-40-6P, N-[3-(Dimethylamino)propyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-methyl-5-methylnicotinamide 878811-41-7P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-N-methyl-5-methyl-N-(1-methylpyrrolidin-3-yl)nicotinamide 878811-42-8P, 1-[[6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]carbonyl]-N,N-dimethylpyrrolidin-3-amine 878811-43-9P, N-[1-[[6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]carbonyl]pyrrolidin-3-yl]acetamide 878811-44-0P, 4-(4-Fluorophenyl)-6-[4-[5-[(4-methoxypiperidin-1-yl)carbonyl]-3-methylpyridin-2-yl]piperazin-1-yl]-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-45-1P, 4-[4-[5-[(4,4-Difluoropiperidin-1-yl)carbonyl]-3-methylpyridin-2-yl]piperazin-1-yl]-6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidine 878811-46-2P 878811-49-5P, 2-[5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]propan-2-ol 878811-51-9P, 1-[5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]ethanol 878811-52-0P 878811-53-1P 878811-54-2P 878811-55-3P, 2-[5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-yl]acetamide 878811-57-5P 878811-58-6P 878811-59-7P 878811-61-1P 878811-62-2P 878811-65-5P 878811-66-6P 878811-67-7P 878811-68-8P 878811-69-9P 878811-70-2P 878811-71-3P 878811-72-4P 878811-73-5P 878811-74-6P 878811-76-8P 878811-77-9P 878811-80-4P 878811-83-7P 878811-85-9P 878811-86-0P 878811-87-1P 878811-88-2P 878811-89-3P 878811-90-6P 878811-91-7P 878811-92-8P 878811-93-9P 878811-94-0P 878811-95-1P

10/719,896


878811-96-2P 878811-97-3P, [6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-yl]methanol

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biaryl piperazinyl-pyridine analogs as type VR1 capsaicin receptor modulators)


RN 833472-70-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878809-39-3 CAPLUS

CN 3-Pyridineacetic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878809-48-4 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878809-56-4 CAPLUS

CN 3-Pyridinemethanamine, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


10/719,896



RN 878809-61-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878809-62-2 CAPLUS

CN 3-Pyridinemethanol, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/719,896


RN 878809-64-4 CAPLUS

CN 3-Pyridinecarboximidamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 878809-65-5 CAPLUS

CN Ethanamine, 2-[[6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 878809-69-9 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 878809-75-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


10/719,896



RN 878809-84-8 CAPLUS

CN 3-Pyridineacetic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878809-92-8 CAPLUS

CN 2-Pyridinecarboxamide, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 878809-96-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-methyl-5-nitro-2-pyridinyl)-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 878810-07-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-18-5 CAPLUS


CN 3-Pyridineethanamine, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-5-fluoro-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878810-20-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)






10/719,896


RN 878810-21-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-22-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-23-2 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-(3-nitro-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 878810-24-3 CAPLUS

CN 4-Pyridinecarboxylic acid, 3-chloro-2-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


10/719,896



RN 878810-25-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878810-26-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/719,896


RN 878810-27-6 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-28-7 CAPLUS

CN 3-Pyridinemethanamine, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 878810-29-8 CAPLUS

CN 3-Pyridinemethanamine, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-30-1 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 878810-31-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-32-3 CAPLUS


CN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-propyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-33-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-propyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


10/719,896



RN 878810-34-5 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878810-35-6 CAPLUS

CN 3-Pyridinemethanamine, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 878810-36-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-


10/719,896

methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 878810-37-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-38-9 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(6-methoxy-3-nitro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 878810-39-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-propyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI)  
(CA INDEX NAME)


10/719,896



RN 878810-40-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 878810-41-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-42-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, ethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 878810-43-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 878810-44-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-45-8 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-46-9 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-47-0 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-48-1 CAPLUS


CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878810-49-2 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



10/719,896

RN 878810-50-5 CAPLUS


CN 3-Pyridinecarboxamide, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-51-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-52-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(5-chloro-3-pyridinyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-53-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-3-methyl-4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878810-54-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)


10/719,896



RN 878810-55-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-3-methyl-4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 878810-56-1 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



-4-[6-(3-methylphenyl)-2-(2-aziryl)-(9CI) (CA INDEX




chloro-3-pyridinyl)-2-(2-  
1-1-piperazinyl]- (9CI) (CA



-4-[6-[2-(1-methylethyl)-4-methyl-2-pyridinyl]-1-piperazinyl]-


10/719,896



RN 878810-60-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-3-methyl-4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-61-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(5-chloro-3-pyridinyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 878810-62-9 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-3-methyl-4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878810-63-0 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 878810-64-1 CAPLUS

10/719,896


CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 878810-65-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-66-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-67-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-68-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-70-9 CAPLUS

CN 3-Pyridinemethanol, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878810-71-0 CAPLUS

CN 3-Pyridinemethanol, 5-methyl-6-[(3R)-3-methyl-4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Chemical structure of a substituted piperazine derivative. The piperazine ring is substituted at the 1-position with a 4-methylphenyl group, at the 2-position with a 4-methyl-2-hydroxyphenyl group, and at the 4-position with a 2-methyl-1,3-dihydroindol-5-yl group. The 3-position of the piperazine ring is substituted with a methyl group (Me) and a variable group R.


CN 3-Pyridinemethanol, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Chemical structure of a substituted piperazine derivative. The piperazine ring is substituted with a 4-(pyridin-2-yl)pyrimidin-2-yl group at one nitrogen, a 4-methyl-2-(hydroxymethyl)pyridin-1-yl group at the other nitrogen, and a 2-methylpyrrolidin-1-yl group at the 4-position. A chiral center is indicated at the 3-position of the piperazine ring with a wedge bond to a methyl group and a label 'R'.

CN 3-Pyridinemethanol, 5-methyl-6-[(3R)-3-methyl-4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-75-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-76-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-77-6 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878810-78-7 CAPLUS


CN 3-Pyridinemethanol, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-79-8 CAPLUS


10/719,896

CN 3-Pyridinemethanol, 5-methyl-6-[4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-80-1 CAPLUS

CN 3-Pyridinemethanol, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-81-2 CAPLUS

CN 3-Pyridinemethanol, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-82-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




10/719,896




RN 878810-83-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-84-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-85-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 878810-86-7 CAPLUS

10/719,896

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878810-88-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-methyl-6-[(3R)-3-methyl-4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878810-93-6 CAPLUS


CN 3-Pyridinecarboxamide, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 878810-94-7 CAPLUS

CN 3-Pyridinecarboxamide, 5-methyl-6-[4-[6-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-95-8 CAPLUS

CN 3-Pyridinecarboxamide, 5-methyl-6-[4-[2-(2-methyl-1-pyrrolidinyl)-6-(4-pyridinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878810-96-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

CN(C)CC1(C)N(C1)c2nc(C3=CC=C(C=C3)N)nc(N4CCN(CC4)c5cc(C(=O)N)nc5)c6cc(C)nc6

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

C[C@H]1CC[C@H](N1c2ncnc2C3=CC=C(C=C3)F)N4CCN(CC4)C5=CC(=CC=C5)N=C(C=C5)C(=O)O

CN 3-Pyridineacetic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


C[C@H]1CC[C@H](N1c2ncnc2C3=CC=C(C=C3)F)N4CCN(CC4)c5cc(Cl)cc(C5)CC(=O)O

RN 878810-99-2 CAPLUS

10/719,896

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 878811-00-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 878811-01-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[2-[(2R)-2-methyl-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896.



RN 878811-02-0 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-03-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-04-2 CAPLUS

CN 3-Pyridineacetonitrile, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-05-3 CAPLUS

CN 3-Pyridineacetic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-06-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-07-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 878811-08-6 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878811-09-7 CAPLUS


CN 3-Pyridinecarboxamide, N-cyclopropyl-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



10/719,896


RN 878811-10-0 CAPLUS

CN 3-Pyridinecarboxamide, N-cyclobutyl-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 878811-11-1 CAPLUS

CN 3-Pyridinecarboxamide, N-cyclopentyl-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 878811-12-2 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 878811-13-3 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-14-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 878811-15-5 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 878811-16-6 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-17-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(4-fluorophenyl)methyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI)  
(CA INDEX NAME)



RN 878811-18-8 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N-[(4-methoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 878811-19-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

10/719,896.




RN 878811-20-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N-(2-methoxy-1-methylethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 878811-21-3 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 878811-22-4 CAPLUS


CN 3-Pyridinecarboxamide, N-(2-ethoxyethyl)-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-23-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 878811-24-6 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,5-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 878811-25-7 CAPLUS


CN Pyrrolidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-26-8 CAPLUS

CN Piperidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 878811-27-9 CAPLUS


CN Morpholine, 4-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 878811-28-0 CAPLUS


CN Piperidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-29-1 CAPLUS

CN 1H-Azepine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]hexahydro- (9CI)  
(CA INDEX NAME)



RN 878811-30-4 CAPLUS


CN Thiomorpholine, 4-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 878811-31-5 CAPLUS


CN Piperidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-2-methyl- (9CI)  
(CA INDEX NAME)






RN 878811-32-6 CAPLUS

CN 3-Pyridinecarboxamide, N-cyclohexyl-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 878811-33-7 CAPLUS


CN Piperidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 878811-34-8 CAPLUS


CN Piperazine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-35-9 CAPLUS

CN Piperazine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 878811-36-0 CAPLUS


CN Piperazine, 1-cyclopentyl-4-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 878811-37-1 CAPLUS


CN Piperazine, 1-acetyl-4-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-38-2 CAPLUS

CN Pyrrolidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-2-methyl- (9CI)  
(CA INDEX NAME)



RN 878811-39-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 878811-40-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-41-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,5-dimethyl-N-(1-methyl-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 878811-42-8 CAPLUS


CN 3-Pyrrolidinamine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 878811-43-9 CAPLUS


CN Acetamide, N-[1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 878811-44-0 CAPLUS

CN Piperidine, 1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 878811-45-1 CAPLUS

CN Piperidine, 4,4-difluoro-1-[[6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 878811-46-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 878811-49-5 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 878811-51-9 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl- (9CI) (CA INDEX NAME)




RN 878811-52-0 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

10/719,896


Absolute stereochemistry.



RN 878811-53-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-54-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 878811-55-3 CAPLUS


CN 3-Pyridineacetamide, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878811-57-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878811-58-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-3-



10/719,896

pyridinyl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878811-59-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-61-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-62-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878811-65-5 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[(2R)-2-methyl-4-[3-methyl-5-(2-oxazolyl)-2-pyridinyl]-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(3R)-4-[2-[2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

CC1CN(C2=CC=CC=C2)CCN(C3=CC=C(C=C3)Cl)C4=CC=CC=C4

CN    Pyrimidine, 4-(4-fluorophenyl)-6-[(2R)-2-methyl-4-[3-methyl-5-(1H-tetrazol-5-yl)-2-pyridinyl]-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Chemical structure of a substituted pyrimidine derivative. The structure features a central piperazine ring. One nitrogen of the piperazine is connected to a 4-chloro-2-(aminocarbonyl)pyrimidin-5-yl group. The other nitrogen is connected to a 2-(4-phenyl-6-(hydroxymethyl)pyrimidin-2-yl)ethyl group, which also has a methyl group attached to the carbon between the nitrogens. The hydroxymethyl group is shown as a dashed line to a CH<sub>2</sub>OH group.

CN 3-Pyridinecarboxamide, 5-chloro-N-(2-hydroxyethyl)-6-[(3R)-4-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-70-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-N-(2-hydroxyethyl)-6-[(3R)-3-methyl-4-[2-[(2R)-2-methyl-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-71-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-methyl-6-[(3R)-3-methyl-4-[6-(4-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-72-4 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[(2R)-4-[5-(1H-imidazol-2-yl)-3-methyl-2-pyridinyl]-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 878811-73-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3S)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-74-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-hydroxyethyl)-5-methyl-6-[(3R)-3-methyl-4-[6-(6-methyl-3-pyridinyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-76-8 CAPLUS

CN 3-Pyridinemethanol, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(1-piperidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-77-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-6-[(2R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-2-methyl-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-80-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-1-piperazinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 878811-83-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-85-9 CAPLUS

CN 3-Pyridineethanol, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-86-0 CAPLUS

CN Ethanol, 2-[[6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-87-1 CAPLUS

CN Ethanol, 2-[[5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-88-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[4-(4-fluorophenyl)-6-[(2R)-4-[5-(2-hydroxyethoxy)-3-methyl-2-pyridinyl]-2-methyl-1-piperazinyl]-2-pyrimidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-89-3 CAPLUS

CN 3-Pyridineethanol, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-90-6 CAPLUS

CN 3-Pyridineethanamine, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-91-7 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878811-92-8 CAPLUS

CN Pyrimidine, 5-fluoro-4-(4-fluorophenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878811-93-9 CAPLUS

CN 3-Pyridineacetic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/719,896



RN 878811-94-0 CAPLUS

CN 2-Propen-1-ol, 3-[5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-3-pyridinyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.




RN 878811-95-1 CAPLUS

CN Ethanol, 2-[[6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl-3-pyridinyl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/719,896



RN 878811-96-2 CAPLUS


CN 3-Pyridinepropanol, 5-chloro-6-[(3R)-4-{6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 878811-97-3 CAPLUS

CN 3-Pyridinemethanol, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



IT 833470-78-3P, 6-[4-[6-(3-Chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-ol  
833471-94-6P, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-


yl]pyrimidin-4-yl]-3-(R)-methylpiperazin-1-yl]-5-methylnicotinonitrile  
 833472-65-4P, 2-[4-[6-(3-Chloro-4-fluorophenyl)-2-(2-  
 methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-bromopyrimidine  
 878809-42-8P, [5-Chloro-6-[4-[6-(4-fluorophenyl)-2-(2-  
 methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyridin-3-  
 yl]acetonitrile 878809-55-3P, 5-Chloro-6-[4-[6-(4-fluorophenyl)-  
 2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]nicotinic acid  
 ethyl ester 878809-57-5P, Methanesulfonic acid  
 [5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-  
 yl]piperazin-1-yl]pyridin-3-yl]methyl ester 878809-60-0P,  
 4-[4-(5-Bromo-3-methylpyridin-2-yl)-2-(R)-methylpiperazin-1-yl]-6-(4-  
 fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidine 878809-63-3P  
 878809-68-8P, [6-[4-[6-(3-Chloro-4-fluorophenyl)-2-(2-  
 methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylpyridin-3-  
 yl]amine 878809-86-0P, 4-[6-(4-Fluorophenyl)-2-(2-(R)-  
 methylpyrrolidin-1-yl)pyrimidin-4-yl]-3-(R)-methylpiperazine-1-carboxylic  
 acid tert-butyl ester 878809-87-1P 878809-88-2P  
 878809-89-3P 878809-91-7P 878809-99-5P,  
 4-[6-(3-Chloro-4-fluorophenyl)-2-(4-propylpiperazin-1-yl)pyrimidin-4-  
 yl]piperazine-1-carboxylic acid tert-butyl ester 878810-00-5P,  
 4-(3-Chloro-4-fluorophenyl)-6-(piperazin-1-yl)-2-(4-propylpiperazin-1-  
 yl)pyrimidine 878810-02-7P 878810-03-8P  
 878810-04-9P 878810-05-0P 878810-11-8P  
 878810-12-9P 878810-14-1P 878810-16-3P  
 878810-17-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(intermediate; preparation of biaryl piperazinyl-pyridine analogs as type  
 VR1 capsaicin receptor modulators)

RN 833470-78-3 CAPLUS

CN 3-Pyridinol, 6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-  
 4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 833471-94-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-  
 pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




10/719,896




RN 833472-65-4 CAPLUS

CN Pyrimidine, 4-[4-(5-bromo-2-pyrimidinyl)-1-piperazinyl]-6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 878809-42-8 CAPLUS


CN 3-Pyridineacetonitrile, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 878809-55-3 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/719,896



RN 878809-57-5 CAPLUS


CN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



RN 878809-60-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(5-bromo-3-methyl-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878809-63-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 878809-68-8 CAPLUS


CN 3-Pyridinamine, 6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 878809-86-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878809-87-1 CAPLUS

10/719,896

CN Pyrimidine, 4-(4-fluorophenyl)-6-[(2R)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878809-88-2 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(5-bromo-3-methyl-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878809-89-3 CAPLUS

CN 3-Pyridineacetic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878809-91-7 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878809-99-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-(3-chloro-4-fluorophenyl)-2-(4-propyl-1-piperazinyl)-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/719,896



RN 878810-00-5 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-(1-piperazinyl)-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 878810-02-7 CAPLUS

CN Morpholine, 4-[4-(4-fluorophenyl)-6-[(2R)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-3-methyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-03-8 CAPLUS

CN Pyrazinecarboxylic acid, 3-amino-6-chloro-5-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-04-9 CAPLUS

CN Pyrazinecarboxylic acid, 3-bromo-6-chloro-5-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-05-0 CAPLUS

CN Pyrazinecarboxylic acid, 6-chloro-5-[(3R)-4-[6-(4-fluorophenyl)-2-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-11-8 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(5-bromo-3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 878810-12-9 CAPLUS

CN 3-Pyridinecarbonitrile, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 878810-14-1 CAPLUS

CN 3-Pyridineacetonitrile, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 878810-16-3 CAPLUS

CN 3-Pyridineacetaldehyde, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 878810-17-4 CAPLUS

CN 3-Pyridineethanamine, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 833471-93-5, 6-[4-[6-(4-Fluorophenyl)-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl]-5-methylnicotinonitrile

878810-06-1, 4-(3-Chloro-4-fluorophenyl)-2-(2-methylpyrrolidin-1-yl)-6-(piperazin-1-yl)pyrimidine


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of biaryl piperazinyl-pyridine analogs as type VR1 capsaicin receptor modulators)

RN 833471-93-5 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

10/719,896




RN 878810-06-1 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



10/719,896


L4 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1294110 CAPLUS  
DN 144:225477  
TI Flux (1): A Virtual Synthesis Scheme for Fragment-Based de Novo Design  
AU Fechner, Uli; Schneider, Gisbert  
CS Institut fuer Organische Chemie und Chemische Biologie, Johann Wolfgang  
Goethe-Universitaet, Frankfurt, D-60439, Germany  
SO Journal of Chemical Information and Modeling (2006), 46(2), 699-707  
CODEN: JCISD8; ISSN: 1549-9596  
PB American Chemical Society  
DT Journal  
LA English  
IT 872672-77-0  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(Flux (1), a virtual synthesis scheme for fragment-based de novo  
design)  
RN 872672-77-0 CAPLUS  
CN Benzamide, 2-[6-(2-methylphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-  
N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896


L4 ANSWER 11 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1250993 CAPLUS  
DN 144:141984  
TI Homology Modeling of the Serotonin 5-HT1A Receptor Using Automated Docking  
of Bioactive Compounds with Defined Geometry  
AU Nowak, Mateusz; Kolaczowski, Marcin; Pawlowski, Maciej; Bojarski, Andrzej  
J.  
CS Department of Medicinal Chemistry, Institute of Pharmacology, Polish  
Academy of Sciences, Krakow, 31-343, Pol.  
SO Journal of Medicinal Chemistry (2006), 49(1), 205-214  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
IT 171115-33-6  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
(Biological study)  
(homol. modeling of 5-HT1A receptor using automated docking of  
bioactive compds. with defined geometry)  
RN 171115-33-6 CAPLUS  
CN Pyrimidine, 4-(2-benzofuranyl)-2-(4-methyl-1-piperazinyl)-6-(1-methyl-1H-  
pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1144487 CAPLUS  
DN 144:51537  
TI A small library of trisubstituted pyrimidines as antimalarial and antitubercular agents  
AU Agarwal, Anu; Srivastava, Kumkum; Puri, S. K.; Sinha, S.; Chauhan, Prem M. S.  
CS Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow, 226001, India  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5218-5221  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 144:51537  
IT 420102-74-5P 871246-01-4P 871246-02-5P  
871246-03-6P 871246-04-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of trisubstituted pyrimidines on solid support as antimalarial and antitubercular agents)  
RN 420102-74-5 CAPLUS  
CN Phenol, 4-[2-(4-morpholinyl)-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 871246-01-4 CAPLUS  
CN Phenol, 4-[6-(4-methylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 871246-02-5 CAPLUS  
CN Phenol, 4-[6-(4-methoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 871246-03-6 CAPLUS

CN Phenol, 4-[6-(3,4-dimethoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 871246-04-7 CAPLUS


CN Phenol, 4-[6-(2,5-dimethoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1084908 CAPLUS  
DN 144:6747  
TI Solid support synthesis of 6-aryl-2-substituted pyrimidin-4-ylphenols as  
anti-infective agents  
AU Agarwal, Anu; Srivastava, Kumkum; Puri, S. K.; Sinha, S.; Chauhan, Prem M.  
S.  
CS Division of Medicinal & Process Chemistry, Central Drug Research  
Institute, Lucknow, 226001, India  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(22), 4923-4926  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 144:6747  
IT 420099-29-2P 869849-61-6P 869849-62-7P  
869849-63-8P 869849-64-9P 869849-65-0P  
869849-66-1P 869849-67-2P 869849-68-3P  
869849-69-4P 869849-70-7P 869849-76-3P  
869849-77-4P 869849-78-5P 869849-79-6P  
869849-80-9P 869849-81-0P 869849-82-1P  
869849-83-2P 869849-84-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(solid-phase synthesis of 2-amino-6-arylpyrimidin-4-ylphenols as  
antitubercular and antimalarial agents)  
RN 420099-29-2 CAPLUS  
CN Phenol, 4-[6-phenyl-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX  
NAME)



RN 869849-61-6 CAPLUS  
CN Phenol, 4-[2-(4-methyl-1-piperazinyl)-6-phenyl-4-pyrimidinyl]- (9CI) (CA  
INDEX NAME)




RN 869849-62-7 CAPLUS




10/719,896

CN Phenol, 4-[6-(4-methylphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 869849-63-8 CAPLUS

CN Phenol, 4-[6-(4-methoxyphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 869849-64-9 CAPLUS


CN Phenol, 4-[6-(3,4-dimethoxyphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 869849-65-0 CAPLUS


CN Phenol, 4-[6-(2,5-dimethoxyphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 869849-66-1 CAPLUS

CN Phenol, 4-[6-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 869849-67-2 CAPLUS


CN Phenol, 4-[6-(4-methylphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-4-  
pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869849-68-3 CAPLUS


CN Phenol, 4-[6-(4-methoxyphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-4-  
pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 869849-69-4 CAPLUS

CN Phenol, 4-[6-(3,4-dimethoxyphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869849-70-7 CAPLUS


CN Phenol, 4-[6-(2,5-dimethoxyphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869849-76-3 CAPLUS


CN Phenol, 4-[6-phenyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 869849-77-4 CAPLUS

CN Phenol, 4-[6-(4-methylphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 869849-78-5 CAPLUS

CN Phenol, 4-[6-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 869849-79-6 CAPLUS


CN Phenol, 4-[6-(3,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 869849-80-9 CAPLUS


CN Phenol, 4-[6-(2,5-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 869849-81-0 CAPLUS

CN Phenol, 4-[6-(4-methylphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 869849-82-1 CAPLUS

CN Phenol, 4-[6-(4-methoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869849-83-2 CAPLUS


CN Phenol, 4-[6-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869849-84-3 CAPLUS

CN Phenol, 4-[6-(2,5-dimethoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/719,896




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:544549 CAPLUS  
DN 143:145813  
TI Synthesis of 2,4,6-trisubstituted pyrimidines as antimalarial agents  
AU Agarwal, Anu; Srivastava, Kumkum; Puri, S. K.; Chauhan, Prem M. S.  
CS Division of Medicinal & Process Chemistry, Central Drug Research  
Institute, Lucknow, 226001, India  
SO Bioorganic & Medicinal Chemistry (2005), 13(15), 4645-4650  
CODEN: BMECEP; ISSN: 0968-0896  
PB Elsevier Ltd.  
DT Journal  
LA English  
OS CASREACT 143:145813  
IT 859844-44-3P 859844-45-4P 859844-46-5P  
859844-47-6P 859844-48-7P 859844-49-8P  
859844-50-1P 859844-51-2P 859844-52-3P  
859844-53-4P 859844-54-5P 859844-55-6P  
859844-56-7P 859844-57-8P 859844-58-9P  
859844-59-0P 859844-60-3P 859844-61-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(synthesis of 2,4,6-trisubstituted pyrimidines as antimalarial agents)  
RN 859844-44-3 CAPLUS  
CN Pyrimidine, 4-phenyl-6-(4-pyridinyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX  
NAME)




RN 859844-45-4 CAPLUS  
CN Pyrimidine, 4-(4-methoxyphenyl)-6-(4-pyridinyl)-2-(1-pyrrolidinyl)- (9CI)  
(CA INDEX NAME)




RN 859844-46-5 CAPLUS  
CN Pyrimidine, 4-(2,5-dimethoxyphenyl)-6-(4-pyridinyl)-2-(1-pyrrolidinyl)-  
(9CI) (CA INDEX NAME)

10/719,896




RN 859844-47-6 CAPLUS

CN Pyrimidine, 4-(4-pyridinyl)-2-(1-pyrrolidinyl)-6-(2,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 859844-48-7 CAPLUS

CN Pyrimidine, 4-(4-pyridinyl)-2-(1-pyrrolidinyl)-6-(3,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)



RN 859844-49-8 CAPLUS

CN Pyrimidine, 4-(4-methylphenyl)-6-(4-pyridinyl)-2-(1-pyrrolidinyl)- (9CI)  
(CA INDEX NAME)




RN 859844-50-1 CAPLUS




10/719,896

CN Pyrimidine, 4-[4-(methylthio)phenyl]-6-(4-pyridinyl)-2-(1-pyrrolidinyl)-  
(9CI) (CA INDEX NAME)




RN 859844-51-2 CAPLUS

CN Pyrimidine, 4-(3,4-dimethylphenyl)-6-(4-pyridinyl)-2-(1-pyrrolidinyl)-  
(9CI) (CA INDEX NAME)




RN 859844-52-3 CAPLUS

CN Pyrimidine, 4-(4-chlorophenyl)-6-(4-pyridinyl)-2-(1-pyrrolidinyl)- (9CI)  
(CA INDEX NAME)



RN 859844-53-4 CAPLUS


CN Pyrimidine, 4-phenyl-2-(1-piperidinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX  
NAME)



RN 859844-54-5 CAPLUS


10/719,896

CN Pyrimidine, 4-(4-methoxyphenyl)-2-(1-piperidinyl)-6-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 859844-55-6 CAPLUS

CN Pyrimidine, 4-(2,5-dimethoxyphenyl)-2-(1-piperidinyl)-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 859844-56-7 CAPLUS


CN Pyrimidine, 2-(1-piperidinyl)-4-(4-pyridinyl)-6-(2,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)



RN 859844-57-8 CAPLUS


CN Pyrimidine, 2-(1-piperidinyl)-4-(4-pyridinyl)-6-(3,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)

10/719,896




RN 859844-58-9 CAPLUS

CN Pyrimidine, 4-(4-methylphenyl)-2-(1-piperidinyl)-6-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 859844-59-0 CAPLUS

CN Pyrimidine, 4-[4-(methylthio)phenyl]-2-(1-piperidinyl)-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 859844-60-3 CAPLUS


CN Pyrimidine, 4-(3,4-dimethylphenyl)-2-(1-piperidinyl)-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 859844-61-4 CAPLUS

CN Pyrimidine, 4-(4-chlorophenyl)-2-(1-piperidinyl)-6-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)


10/719,896




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:511390 CAPLUS  
DN 143:193967  
TI Synthesis of substituted indole derivatives as a new class of antimalarial agents  
AU Agarwal, Anu; Srivastava, Kumkum; Puri, S. K.; Chauhan, Prem M. S.  
CS Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow, 226001, India  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(12), 3133-3136  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 143:193967  
IT 861888-51-9P 861888-53-1P 861888-55-3P  
861888-57-5P 861888-59-7P 861888-61-1P  
861888-63-3P 861888-64-4P 861888-65-5P  
861888-66-6P 861888-68-8P 861888-70-2P  
861888-71-3P 861888-73-5P 861888-74-6P  
861888-75-7P 861888-76-8P 861888-77-9P  
861888-78-0P 861888-79-1P 861888-80-4P  
861888-81-5P 861888-82-6P 861888-83-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of substituted (indolyl)pyrimidine derivs. and study of their antimalarial activity)  
RN 861888-51-9 CAPLUS  
CN 1H-Indole, 3-[2-(4-methyl-1-piperazinyl)-6-phenyl-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 861888-53-1 CAPLUS  
CN 1H-Indole, 3-[6-(4-methylphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 861888-55-3 CAPLUS  
CN 1H-Indole, 3-[6-(4-methoxyphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 861888-57-5 CAPLUS

CN 1H-Indole, 3-[6-(3,4-dimethoxyphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-59-7 CAPLUS


CN 1H-Indole, 3-[6-(2,5-dimethoxyphenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-61-1 CAPLUS


CN 1H-Indole, 3-[6-(4-chlorophenyl)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 861888-63-3 CAPLUS

CN 1H-Indole, 3-[6-phenyl-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 861888-64-4 CAPLUS

CN 1H-Indole, 3-[6-(4-methylphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-65-5 CAPLUS


CN 1H-Indole, 3-[6-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-66-6 CAPLUS


CN 1H-Indole, 3-[6-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 861888-68-8 CAPLUS

CN 1H-Indole, 3-[6-(2,5-dimethoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 861888-70-2 CAPLUS

CN 1H-Indole, 3-[6-(4-chlorophenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 861888-71-3 CAPLUS

CN 1H-Indole, 3-[6-phenyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX  
NAME)




RN 861888-73-5 CAPLUS

CN 1H-Indole, 3-[6-(4-methylphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




10/719,896




RN 861888-74-6 CAPLUS

CN 1H-Indole, 3-[6-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 861888-75-7 CAPLUS

CN 1H-Indole, 3-[6-(3,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-76-8 CAPLUS


CN 1H-Indole, 3-[6-(2,5-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-77-9 CAPLUS


CN 1H-Indole, 3-[6-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)

10/719,896




RN 861888-78-0 CAPLUS

CN 1H-Indole, 3-[2-(4-morpholinyl)-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 861888-79-1 CAPLUS

CN 1H-Indole, 3-[6-(4-methylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-80-4 CAPLUS


CN 1H-Indole, 3-[6-(4-methoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 861888-81-5 CAPLUS


CN 1H-Indole, 3-[6-(3,4-dimethoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 861888-82-6 CAPLUS

CN 1H-Indole, 3-[6-(2,5-dimethoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 861888-83-7 CAPLUS


CN 1H-Indole, 3-[6-(4-chlorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:511389 CAPLUS  
DN 143:172835  
TI Antimalarial activity and synthesis of new trisubstituted pyrimidines  
AU Agarwal, Anu; Srivastava, Kumkum; Puri, S. K.; Chauhan, Prem M. S.  
CS Division of Medicinal and Process Chemistry, Central Drug Research  
Institute, Lucknow, 226001, India  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(12), 3130-3132  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 143:172835  
IT 861429-93-8P 861429-94-9P 861429-95-0P  
861429-96-1P 861429-97-2P 861429-98-3P  
861429-99-4P 861430-00-4P 861430-01-5P  
861430-02-6P 861430-03-7P 861430-04-8P  
861430-05-9P 861430-06-0P 861430-07-1P  
861430-08-2P 861430-09-3P 861430-10-6P  
861430-11-7P 861430-12-8P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic  
preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, antimalarial activity and structure-activity relationship of  
piperazinyipyridinylpyrimidines using heterocyclization of  
pyridylchalcones and piperazinecarboxamides as key step)  
RN 861429-93-8 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-phenyl-6-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 861429-94-9 CAPLUS  
CN Pyrimidine, 4-(4-methylphenyl)-2-(4-methyl-1-piperazinyl)-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)




RN 861429-95-0 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-[4-(methylthio)phenyl]-6-(4-  
pyridinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 861429-96-1 CAPLUS

CN Pyrimidine, 4-(3,4-dimethylphenyl)-2-(4-methyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 861429-97-2 CAPLUS


CN Pyrimidine, 4-(4-methoxyphenyl)-2-(4-methyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 861429-98-3 CAPLUS


CN Pyrimidine, 4-(2,5-dimethoxyphenyl)-2-(4-methyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 861429-99-4 CAPLUS

CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(4-pyridinyl)-6-(2,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 861430-00-4 CAPLUS


CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(4-pyridinyl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 861430-01-5 CAPLUS


CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(3-nitrophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 861430-02-6 CAPLUS

CN Pyrimidine, 4-(4-chlorophenyl)-2-(4-methyl-1-piperazinyl)-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)




RN 861430-03-7 CAPLUS

CN Pyrimidine, 4-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 861430-04-8 CAPLUS


CN Pyrimidine, 4-(4-methylphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



10/719,896


RN 861430-05-9 CAPLUS

CN Pyrimidine, 4-[4-(methylthio)phenyl]-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 861430-06-0 CAPLUS

CN Pyrimidine, 4-(3,4-dimethylphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 861430-07-1 CAPLUS

CN Pyrimidine, 4-(4-methoxyphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 861430-08-2 CAPLUS

CN Pyrimidine, 4-(2,5-dimethoxyphenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




10/719,896




RN 861430-09-3 CAPLUS

CN Pyrimidine, 2-[4-(phenylmethyl)-1-piperazinyl]-4-(4-pyridinyl)-6-(2,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 861430-10-6 CAPLUS


CN Pyrimidine, 2-[4-(phenylmethyl)-1-piperazinyl]-4-(4-pyridinyl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 861430-11-7 CAPLUS


CN Pyrimidine, 4-(3-nitrophenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

10/719,896



RN 861430-12-8 CAPLUS

CN Pyrimidine, 4-(4-chlorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:451376 CAPLUS  
DN 142:482069  
TI Preparation of quinoxazolines and related derivatives vanilloid-1 receptor antagonists for treating pain  
IN Hollingworth, Gregory John; Jones, Brian A.; McIver, Edward Giles; Moyes, Christopher Richard; Rogers, Lauren  
PA Merck Sharp & Dohme Limited, UK  
SO PCT Int. Appl., 108 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005047279	A1	20050526	WO 2004-GB4719	20041109
	WO 2005047279	A8	20060810		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004289518	A1	20050526	AU 2004-289518	20041109
	CA 2545384	A1	20050526	CA 2004-2545384	20041109
	US 2005197342	A1	20050908	US 2004-984336	20041109
	EP 1685124	A1	20060802	EP 2004-798442	20041109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
PRAI	GB 2003-26217	A	20031110		
	GB 2004-7748	A	20040405		
	US 2004-617134P	P	20041008		
	WO 2004-GB4719	W	20041109		
OS	MARPAT 142:482069				
IT	852062-74-9P, 5-Methyl-2-(2-methylpyrrolidin-1-yl)-6-(quinolin-7-yl)-N-(5-trifluoromethylpyridin-2-yl)pyrimidin-4-amine				
	852062-75-0P, 5-Methyl-2-morpholin-4-yl-6-(quinolin-7-yl)-N-(5-trifluoromethylpyridin-2-yl)pyrimidin-4-amine				
	852062-82-9P, 2-(Morpholin-4-yl)-6-(quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)				
RN	852062-74-9 CAPLUS				
CN	4-Pyrimidinamine, 5-methyl-2-(2-methyl-1-pyrrolidinyl)-6-(7-quinolinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)				


10/719,896



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852062-75-0 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-2-(4-morpholinyl)-6-(7-quinolinyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852062-82-9 CAPLUS

CN 4-Pyrimidinamine, 2-(4-morpholinyl)-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:395305 CAPLUS

DN 142:463737

TI Preparation of 4-(pyrazol-3-ylamino)pyrimidines for use in the treatment of cancer

IN Nowak, Thorsten; Thomas, Andrew Peter

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 272 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040159	A1	20050506	WO 2004-GB4307	20041011
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283137	A1	20050506	AU 2004-283137	20041011
	CA 2542522	A1	20050506	CA 2004-2542522	20041011
	EP 1678169	A1	20060712	EP 2004-768838	20041011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004015398	A	20061219	BR 2004-15398	20041011
	CN 1894243	A	20070110	CN 2004-80037801	20041011
	NO 2006002130	A	20060512	NO 2006-2130	20060512
	US 2007037888	A1	20070215	US 2006-595390	20060906
PRAI	GB 2003-24335	A	20031017		
	GB 2004-12194	A	20040602		
	WO 2004-GB4307	W	20041011		
OS	MARPAT 142:463737				
IT	851432-75-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 4-(pyrazol-3-ylamino)pyrimidines for use in the treatment of cancer)				
RN	851432-75-2 CAPLUS				
CN	4-Pyrimidinamine, 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-[3-(2-pyridinyl)-5-isoxazolyl]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)				


10/719,896



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:339544 CAPLUS  
DN 143:48228  
TI Structure-enantioselectivity relationship of hypnotic-sedative  
1,4-disubstituted piperazine derivatives on cellulose tris(4-  
methylbenzoate) chiral stationary phase  
AU Chilmonczyk, Zdzisław; Ksycinska, Hanna; Lisowska-Kuzmich, Malgorzata;  
Jonczyk, Anna; Mazgajska, Maria; Jaronczyk, Malgorzata; Strzelczyk, Anna;  
Aboul-Enein, Hassan Y.  
CS National Institute of Public Health, Warsaw, 00-725, Pol.  
SO Analytica Chimica Acta (2005), 536(1-2), 7-13  
CODEN: ACACAM; ISSN: 0003-2670  
PB Elsevier B.V.  
DT Journal  
LA English  
IT 853562-00-2  
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL  
(Biological study); USES (Uses)  
(structure-enantioselectivity relationship of sedative  
1,4-disubstituted piperazine derivs. on cellulose tris(4-  
methylbenzoate) chiral stationary phase)  
RN 853562-00-2 CAPLUS  
CN Piperazine, 1-(2-acetyl-1-oxoheptyl)-4-(4,6-di-2-furanyl-2-pyrimidinyl)-  
(9CI) (CA INDEX NAME)




RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:300452 CAPLUS  
DN 142:349111  
TI Pyrazolopyrrole derivatives as protein kinase inhibitors, and their  
therapeutic use  
IN Binch, Hayley; Everitt, Simon; Mazzei, Francesca; Robinson, Daniel  
PA Vertex Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 72 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030776	A1	20050407	WO 2004-US31610	20040923
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004276341	A1	20050407	AU 2004-276341	20040923
	CA 2539549	A1	20050407	CA 2004-2539549	20040923
	US 2005101594	A1	20050512	US 2004-949714	20040923
	EP 1668013	A1	20060614	EP 2004-785111	20040923
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-505236P	P	20030923		
	WO 2004-US31610	W	20040923		
OS	MARPAT 142:349111				
IT	849102-69-8 849102-70-1 849102-71-2 849102-72-3 849102-73-4 849102-74-5 849102-75-6 849102-76-7				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrazolopyrrole derivative protein kinase inhibitors, and therapeutic use)				
RN	849102-69-8 CAPLUS				
CN	Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(2-pyrimidinyl)-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE




10/719,896

RN 849102-70-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-benzoyl-1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-71-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-72-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-acetyl-1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-73-4 CAPLUS

10/719,896

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(1-oxopropyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-74-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-75-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 849102-76-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-

10/719,896

(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:244474 CAPLUS

DN 142:463686

TI Antimalarial activity of 2,4,6-trisubstituted pyrimidines

AU Agarwal, Anu; Srivastava, Kumkum; Puri, S. K.; Chauhan, Prem M. S.

CS Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow, 226001, India

SO Bioorganic & Medicinal Chemistry Letters (2005), 15(7), 1881-1883  
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 142:463686

IT 851663-38-2P 851663-39-3P 851663-40-6P

851663-41-7P 851663-42-8P 851663-43-9P

851663-44-0P 851663-45-1P 851663-46-2P

851663-47-3P 851663-48-4P 851663-49-5P


851663-50-8P 851663-51-9P 851663-52-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimalarial activity of pyrimidines via condensation of acetylpyridine with arylaldehydes followed by heterocyclization with morpholinecarboxamide and aromatization)


RN 851663-38-2 CAPLUS

CN Morpholine, 4-[4-phenyl-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 851663-39-3 CAPLUS


CN Morpholine, 4-[4-(4-methoxyphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 851663-40-6 CAPLUS


CN Morpholine, 4-[4-(3-methoxyphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 851663-41-7 CAPLUS

CN Morpholine, 4-[4-(2,3-dimethoxyphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 851663-42-8 CAPLUS


CN Morpholine, 4-[4-(2,5-dimethoxyphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 851663-43-9 CAPLUS


CN Morpholine, 4-[4-(3,5-dimethoxyphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 851663-44-0 CAPLUS

CN Morpholine, 4-[4-(4-pyridinyl)-6-(2,4,5-trimethoxyphenyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 851663-45-1 CAPLUS

CN Morpholine, 4-[4-(4-pyridinyl)-6-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 851663-46-2 CAPLUS


CN Morpholine, 4-[4-(4-methylphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 851663-47-3 CAPLUS


10/719,896

CN Morpholine, 4-[4-[4-(methylthio)phenyl]-6-(4-pyridinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 851663-48-4 CAPLUS

CN Morpholine, 4-[4-(3,4-dimethylphenyl)-6-(4-pyridinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 851663-49-5 CAPLUS

CN Morpholine, 4-[4-(4-methoxy-1-naphthalenyl)-6-(4-pyridinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 851663-50-8 CAPLUS


CN Morpholine, 4-[4-(4-chlorophenyl)-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



10/719,896


RN 851663-51-9 CAPLUS

CN Morpholine, 4-[4-(3-nitrophenyl)-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 851663-52-0 CAPLUS

CN Morpholine, 4-[4-(4-pyridinyl)-6-(2-thienyl)-2-pyrimidinyl]- (9CI) (CA  
INDEX NAME)




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/719,896


L4 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:99484 CAPLUS  
DN 142:198089  
TI Preparation of azinyl aryl amines as vanilloid receptor ligands.  
IN Blum, Charles A.; Brielmann, Harry; Hodgetts, Kevin J.  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009977	A1	20050203	WO 2004-US22820	20040715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259712	A1	20050203	AU 2004-259712	20040715
	CA 2531490	A1	20050203	CA 2004-2531490	20040715
	EP 1651619	A1	20060503	EP 2004-778364	20040715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1823048	A	20060823	CN 2004-80020429	20040715
	US 2006229308	A1	20061012	US 2006-564583	20060406
PRAI	US 2003-487405P	P	20030715		
	WO 2004-US22820	W	20040715		
OS	CASREACT 142:198089; MARPAT 142:198089				
IT	837382-72-6P 837382-74-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of azinyl aryl amines as vanilloid receptor ligands)				
RN	837382-72-6 CAPLUS				
CN	4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)-5-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)				



RN 837382-74-8 CAPLUS.  
CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-5-methyl-2-(4-morpholinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10/719,896



RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:71173 CAPLUS

DN 142:176866

TI Preparation of biaryl piperazinyl-pyridine analogues as capsaicin receptor modulators

IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Chenard, Bertrand L.; De Lombaert, Stephane; Hodgetts, Kevin J.; Hutchison, Alan; Yoon, Taeyoung; Zheng, Xiaozhang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 381 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007648	A2	20050127	WO 2004-US23064	20040716
	WO 2005007648	A3	20050324		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004257289	A1	20050127	AU 2004-257289	20040716
	CA 2531619	A1	20050127	CA 2004-2531619	20040716
	EP 1644358	A2	20060412	EP 2004-778532	20040716
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1823057	A	20060823	CN 2004-80020350	20040716
	US 2007027155	A1	20070201	US 2004-893799	20040716
PRAI	US 2003-488564P	P	20030716		
	US 2003-516135P	P	20031031		
	WO 2004-US23064	W	20040716		

OS MARPAT 142:176866


IT 833470-78-3P 833472-18-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators)

RN 833470-78-3 CAPLUS

CN 3-Pyridinol, 6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)




10/719,896

RN 833472-18-7 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-6-methoxy-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 833462-68-3P 833463-14-2P 833463-15-3P  
833463-23-3P 833463-34-6P 833463-35-7P  
833463-36-8P 833463-37-9P 833463-39-1P  
833463-40-4P 833463-41-5P 833463-42-6P  
833463-43-7P 833463-44-8P 833463-45-9P  
833463-46-0P 833463-58-4P 833463-59-5P  
833463-60-8P 833463-61-9P 833463-62-0P  
833463-63-1P 833463-64-2P 833463-65-3P  
833463-67-5P 833463-68-6P 833463-70-0P  
833463-71-1P 833463-72-2P 833463-73-3P  
833463-74-4P 833463-77-7P 833463-79-9P  
833463-80-2P 833463-81-3P 833463-82-4P  
833463-83-5P 833463-84-6P 833463-85-7P  
833463-86-8P 833463-87-9P 833463-88-0P  
833463-89-1P 833463-90-4P 833463-91-5P  
833463-93-7P 833463-94-8P 833463-95-9P  
833463-96-0P 833464-25-8P 833464-26-9P  
833467-46-2P 833467-47-3P 833467-48-4P  
833467-49-5P 833467-50-8P 833467-51-9P  
833467-52-0P 833467-53-1P 833467-54-2P  
833467-55-3P 833467-56-4P 833467-57-5P  
833467-58-6P 833467-59-7P 833467-60-0P  
833467-61-1P 833467-62-2P 833467-63-3P  
833467-64-4P 833467-65-5P 833467-66-6P  
833467-67-7P 833467-68-8P 833467-69-9P  
833467-70-2P 833467-71-3P 833467-72-4P  
833467-73-5P 833467-74-6P 833467-75-7P  
833467-76-8P 833467-77-9P 833467-78-0P  
833467-79-1P 833467-80-4P 833467-81-5P  
833467-82-6P 833467-83-7P 833467-84-8P  
833467-85-9P 833467-86-0P 833467-87-1P  
833467-88-2P 833467-89-3P 833467-90-6P  
833467-91-7P 833467-92-8P 833467-93-9P  
833467-94-0P 833467-95-1P 833467-96-2P  
833467-97-3P 833467-98-4P 833467-99-5P

10/719,896

833468-00-1P 833468-01-2P 833468-02-3P  
833468-03-4P 833468-04-5P 833468-05-6P  
833468-06-7P 833468-07-8P 833468-08-9P  
833468-09-0P 833468-10-3P 833468-11-4P  
833468-13-6P 833468-14-7P 833468-17-0P  
833468-18-1P 833468-28-3P 833468-33-0P  
833468-34-1P 833468-36-3P 833468-39-6P  
833468-40-9P 833468-41-0P 833468-42-1P  
833468-44-3P 833468-48-7P 833468-50-1P  
833468-51-2P 833468-52-3P 833468-53-4P  
833468-54-5P 833468-55-6P 833468-57-8P  
833468-58-9P 833468-63-6P 833468-64-7P  
833468-67-0P 833468-68-1P 833468-71-6P  
833468-73-8P 833468-74-9P 833468-75-0P  
833468-76-1P 833468-77-2P 833468-78-3P  
833468-79-4P 833468-88-5P 833468-89-6P  
833468-90-9P 833468-91-0P 833468-92-1P  
833468-93-2P 833468-94-3P 833468-95-4P  
833468-96-5P 833468-97-6P 833468-99-8P  
833469-01-5P 833469-06-0P 833469-07-1P  
833469-08-2P 833469-10-6P 833469-11-7P  
833469-17-3P 833469-19-5P 833469-22-0P  
833469-24-2P 833469-26-4P 833469-28-6P  
833469-29-7P 833469-32-2P 833469-33-3P  
833469-34-4P 833469-39-9P 833469-40-2P  
833469-41-3P 833469-42-4P 833469-45-7P  
833469-47-9P 833469-59-3P 833469-60-6P  
833469-61-7P 833469-62-8P 833469-63-9P  
833469-64-0P 833469-67-3P 833469-68-4P  
833469-69-5P 833469-70-8P 833469-71-9P  
833469-72-0P 833469-73-1P 833469-74-2P  
833469-76-4P 833469-77-5P 833469-78-6P  
833469-79-7P 833469-80-0P 833469-81-1P  
833469-82-2P 833469-83-3P 833469-84-4P  
833469-85-5P 833469-91-3P 833469-92-4P  
833469-93-5P 833469-95-7P 833469-96-8P  
833469-97-9P 833469-98-0P 833469-99-1P  
833470-05-6P 833470-06-7P 833470-07-8P  
833470-08-9P 833470-09-0P 833470-12-5P  
833470-13-6P 833470-14-7P 833470-15-8P  
833470-16-9P 833470-17-0P 833470-18-1P  
833470-19-2P 833470-23-8P 833470-24-9P  
833470-25-0P 833470-27-2P 833470-28-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor  
modulators)

RN 833462-68-3 CAPLUS


CN 2-Pyridinamine, 5-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-  
pyridinyl]-1-piperazinyl]-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)

10/719,896




RN 833463-14-2 CAPLUS

CN Benzonitrile, 3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-15-3 CAPLUS

CN Benzoic acid, 3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 833463-23-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(3,4-difluorophenyl)-2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



10/719,896

RN 833463-34-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(3-chlorophenyl)-2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833463-35-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3-chlorophenyl)-6-[(2S)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833463-36-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3-chlorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833463-37-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3-chlorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 833463-39-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3-fluoro-4-methylphenyl)-2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833463-40-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3-fluorophenyl)-2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




10/719,896




RN 833463-41-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-fluorophenyl)-2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833463-42-6 CAPLUS


CN Morpholine, 4-[4-(2-fluorophenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-43-7 CAPLUS


CN Morpholine, 4-[4-(3,4-difluorophenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833463-44-8 CAPLUS

CN Morpholine, 4-[4-(3-chlorophenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-45-9 CAPLUS


CN Morpholine, 4-[4-(3-methoxyphenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-46-0 CAPLUS


CN Morpholine, 4-[4-(4-chlorophenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833463-58-4 CAPLUS

CN Morpholine, 4-[4-(2-chloro-4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-59-5 CAPLUS

CN Morpholine, 4-[4-(2-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-60-8 CAPLUS


CN Morpholine, 4-[4-(2-methoxy-4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 833463-61-9 CAPLUS

CN Morpholine, 4-[4-(3,4-difluorophenyl)-5-methyl-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-62-0 CAPLUS

CN Morpholine, 4-[4-(3,4-difluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-63-1 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-5-methyl-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-64-2 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833463-65-3 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-67-5 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-(3-fluoro-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-68-6 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896



RN 833463-70-0 CAPLUS


CN Morpholine, 4-[4-(3-chlorophenyl)-5-methyl-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-71-1 CAPLUS

CN Morpholine, 4-[4-(3-chlorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833463-72-2 CAPLUS

CN Morpholine, 4-[4-(3-chlorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833463-73-3 CAPLUS

CN Morpholine, 4-[4-(3-chlorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-74-4 CAPLUS


CN Morpholine, 4-[4-(3-chlorophenyl)-6-[4-(3-fluoro-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-77-7 CAPLUS


CN Morpholine, 4-[4-(3-chlorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833463-79-9 CAPLUS

CN Morpholine, 4-[4-[3-(ethylsulfonyl)phenyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-80-2 CAPLUS

CN Morpholine, 4-[4-[3-(3-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-81-3 CAPLUS

CN Morpholine, 4-[4-[3-(methylsulfonyl)phenyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-82-4 CAPLUS




10/719,896

CN Morpholine, 4-[4-(3-methoxyphenyl)-5-methyl-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-83-5 CAPLUS

CN Morpholine, 4-[4-(3-methoxyphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-84-6 CAPLUS

CN Morpholine, 4-[4-[3-(trifluoromethyl)phenyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-85-7 CAPLUS


CN Morpholine, 4-[4-(4-chloro-3-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 833463-86-8 CAPLUS

CN Morpholine, 4-[4-(4-chlorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-87-9 CAPLUS

CN Morpholine, 4-[4-[4-(ethylsulfonyl)phenyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-88-0 CAPLUS


CN Morpholine, 4-[4-(4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-89-1 CAPLUS


CN Morpholine, 4-[4-(4-methoxyphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833463-90-4 CAPLUS

CN Morpholine, 4-[4-(6-fluoro-3-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-91-5 CAPLUS

CN Morpholine, 4-[4-(6-methoxy-3-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-93-7 CAPLUS


CN Morpholine, 4-[4-(3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833463-94-8 CAPLUS


CN Morpholine, 4-[4-(2-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833463-95-9 CAPLUS

CN Morpholine, 4-[4-(3-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833463-96-0 CAPLUS

CN Morpholine, 4-[4-(4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833464-25-8 CAPLUS


CN Benzenemethanamine, N,N-diethyl-3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896

RN 833464-26-9 CAPLUS


CN 2-Pyridinamine, N,N-diethyl-4-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833467-46-2 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-47-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-48-4 CAPLUS

CN Morpholine, 4-[4-(3-chlorophenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-49-5 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(4-chlorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-50-8 CAPLUS

CN Morpholine, 4-[4-(4-chlorophenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-51-9 CAPLUS

CN Morpholine, 4-[4-(4-chlorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-52-0 CAPLUS

CN Morpholine, 4-[4-(4-chlorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-53-1 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833467-54-2 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-55-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-56-4 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-3-methyl-4-[2-(4-morpholinyl)-6-(2-naphthalenyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833467-57-5 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-6-(2-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Cc1cc(C2=CN(C2C3=CC=CC=C3)C4=CC=CC=C4)C=C(C=C1)N5CCN(C5)C


CN Morpholine, 4-[4-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-6-(2-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

CN1CCN(C1c2cc(C(F)(F)F)ccn2)C3=CN(C=C(N3)C4=CC=CC=C5C=CC=CC=C45)C6=CC=CC=CC6

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(2-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-60-0 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(3-fluoro-4-methylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-61-1 CAPLUS

CN Morpholine, 4-[4-(3-fluoro-4-methylphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-62-2 CAPLUS

CN Morpholine, 4-[4-(3-fluoro-4-methylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-63-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-64-4 CAPLUS

CN Morpholine, 4-[4-(4-fluoro-3-methylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-65-5 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-66-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-3-methyl-4-[6-[3-(1-methylethyl)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-67-7 CAPLUS

CN Morpholine, 4-[4-[3-(1-methylethyl)phenyl]-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-68-8 CAPLUS

CN Morpholine, 4-[4-[3-(1-methylethyl)phenyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-69-9 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-[3-(1-methylethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833467-70-2 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-3-methyl-4-[6-[4-(1-methylethyl)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-71-3 CAPLUS

CN Morpholine, 4-[4-[4-(1-methylethyl)phenyl]-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-72-4 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-[4-(1-methylethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-73-5 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(3,4-dimethylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-74-6 CAPLUS

CN Morpholine, 4-[4-(3,4-dimethylphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-75-7 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-dimethylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-76-8 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(4-ethylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-77-9 CAPLUS

CN Morpholine, 4-[4-(4-ethylphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-78-0 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-ethylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-79-1 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-3-methyl-4-[2-(4-morpholinyl)-6-(4-propylphenyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-80-4 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-propylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-81-5 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(3-ethylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-82-6 CAPLUS

CN Morpholine, 4-[4-(3-ethylphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-83-7 CAPLUS

CN Morpholine, 4-[4-(3-ethylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-84-8 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-ethylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-85-9 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-[4-(1,1-dimethylethyl)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833467-86-0 CAPLUS

CN Morpholine, 4-[4-[4-(1,1-dimethylethyl)phenyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-87-1 CAPLUS

CN Morpholine, 4-[4-[4-(1,1-dimethylethyl)phenyl]-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-88-2 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-6-(1-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-89-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-6-(4-methyl-1-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-90-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-4-[6-(3-methoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-91-7 CAPLUS

CN Morpholine, 4-[4-(3-methoxyphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-92-8 CAPLUS

CN Morpholine, 4-[4-(3-methoxyphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-93-9 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-94-0 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-6-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-95-1 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-6-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-96-2 CAPLUS

CN Morpholine, 4-[4-(3-ethoxyphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-97-3 CAPLUS

CN Morpholine, 4-[4-(3-ethoxyphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833467-98-4 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-ethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833467-99-5 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-3-methyl-4-[2-(4-morpholinyl)-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833468-00-1 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-6-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833468-01-2 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-6-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833468-02-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833468-03-4 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3R)-3-methyl-4-[6-[3-(methylthio)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833468-04-5 CAPLUS

CN Morpholine, 4-[4-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-6-[3-(methylthio)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833468-05-6 CAPLUS

CN Morpholine, 4-[4-[3-(methylthio)phenyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833468-06-7 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-[3-(methylthio)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833468-07-8 CAPLUS

CN Morpholine, 4-[4-(3-fluoro-4-methoxyphenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833468-08-9 CAPLUS

CN Morpholine, 4-[4-(3-fluoro-4-methoxyphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833468-09-0 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833468-10-3 CAPLUS

CN Morpholine, 4-[4-[3-(1-methylethoxy)phenyl]-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833468-11-4 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-[3-(1-methylethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833468-13-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-14-7 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(4-propyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833468-17-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833468-18-1 CAPLUS


CN L-Proline, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833468-28-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 833468-33-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-

10/719,896


(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 833468-34-1 CAPLUS

CN 3-Pyrrolidinamine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-36-3 CAPLUS

CN Acetamide, N-[1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 833468-39-6 CAPLUS




10/719,896

CN Morpholine, 4-[4-phenyl-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833468-40-9 CAPLUS

CN Morpholine, 4-[4-(2-methyl-4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833468-41-0 CAPLUS

CN Morpholine, 4-[4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-42-1 CAPLUS


CN Morpholine, 4-[4-(2-ethoxy-4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-44-3 CAPLUS


CN 1H-Azepine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]hexahydro-3,3,5-trimethyl- (9CI) (CA INDEX NAME)

10/719,896




RN 833468-48-7 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833468-50-1 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-51-2 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-(3-methoxy-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 833468-52-3 CAPLUS

CN 3-Pyridinamine, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833468-53-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 833468-54-5 CAPLUS


CN Benzenamine, 3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-55-6 CAPLUS


CN Morpholine, 4-[4-(2,6-dimethyl-4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833468-57-8 CAPLUS

CN Morpholine, 4-[4-[2-(1-methylethyl)-4-pyridinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833468-58-9 CAPLUS

CN Morpholine, 4-[4-(5-chloro-3-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-63-6 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[4-(1-methylethyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 833468-64-7 CAPLUS

CN Morpholine, 4-[4-(1-oxido-4-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833468-67-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(1-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-68-1 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-71-6 CAPLUS


CN Morpholine, 4-[4-(6-methyl-3-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833468-73-8 CAPLUS

CN Pyrimidine, 4-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-(1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-74-9 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833468-75-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833468-76-1 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-77-2 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(3,3-dimethyl-1-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-78-3 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-ethyl-1-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833468-79-4 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(3-methyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-88-5 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(4-ethyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833468-89-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[4-(cyclopropylmethyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




10/719,896




RN 833468-90-9 CAPLUS

CN Piperazine, 1-acetyl-4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-91-0 CAPLUS

CN Piperazine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 833468-92-1 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896


Absolute stereochemistry.



RN 833468-93-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-[(2S,5R)-2,4,5-trimethyl-1-piperazinyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 833468-94-3 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833468-95-4 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2,4-dimethyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-96-5 CAPLUS


CN Morpholine, 4-[4-(5-methyl-3-pyridinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-97-6 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[3-methyl-4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833468-99-8 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(3,4-dimethyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-01-5 CAPLUS


CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 833469-06-0 CAPLUS


CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(3-methyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-07-1 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-08-2 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 833469-10-6 CAPLUS


CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-11-7 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[3-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833469-17-3 CAPLUS


CN 1-Piperazineacetamide, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 833469-19-5 CAPLUS


CN Piperazinone, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-22-0 CAPLUS

CN Piperazine, 1-[4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-(1-iminoethyl)- (9CI) (CA INDEX NAME)



RN 833469-24-2 CAPLUS


CN Piperazinone, 4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 833469-26-4 CAPLUS


CN Piperazinone, 4-[6-(3-chloro-4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

10/719,896



RN 833469-28-6 CAPLUS


CN Piperazine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-(1-iminoethyl)- (9CI) (CA INDEX NAME)



RN 833469-29-7 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833469-32-2 CAPLUS

CN Pyrimidine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




10/719,896




RN 833469-33-3 CAPLUS

CN 2-Pyrrolidinone, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833469-34-4 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2,5-dimethyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-39-9 CAPLUS


CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-40-2 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(1-piperidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-41-3 CAPLUS


CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-42-4 CAPLUS


CN Pyrimidine, 2-(2,5-dimethyl-1-pyrrolidinyl)-4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-45-7 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833469-47-9 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(4-propyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833469-59-3 CAPLUS

CN 2-Pyrrolidinemethanamine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833469-60-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833469-61-7 CAPLUS


CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833469-62-8 CAPLUS


CN Pyrimidine, 4-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-63-9 CAPLUS

CN Pyrimidine, 4-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 833469-64-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2,2-dimethyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-67-3 CAPLUS


CN Pyrimidine, 4-(4-fluorophenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833469-68-4 CAPLUS


CN Pyrimidine, 4-(3,4-difluorophenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-69-5 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833469-70-8 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-71-9 CAPLUS


CN Pyrimidine, 4-(3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-72-0 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-fluoro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 833469-73-1 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-6-[4-(3-fluoro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833469-74-2 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833469-76-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833469-77-5 CAPLUS


CN 2-Pyrrolidinemethanamine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833469-78-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 833469-79-7 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




10/719,896




RN 833469-80-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 833469-81-1 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-[4-(1-methylethyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-82-2 CAPLUS

CN Pyrimidine, 4-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 833469-83-3 CAPLUS

10/719,896

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833469-84-4 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833469-85-5 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833469-91-3 CAPLUS

CN Pyrimidine, 4-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833469-92-4 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833469-93-5 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 833469-95-7 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833469-96-8 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833469-97-9 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833469-98-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833469-99-1 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-05-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-06-7 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833470-07-8 CAPLUS

CN Morpholine, 4-[4-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-pyrimidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 833470-08-9 CAPLUS

CN Pyrimidine, 4-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 833470-09-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896




RN 833470-12-5 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-6-[4-(3-fluoro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833470-13-6 CAPLUS


CN Pyrimidine, 4-(4-fluorophenyl)-6-[4-(3-fluoro-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833470-14-7 CAPLUS


CN 1-Piperazineethanol, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896



RN 833470-15-8 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-chloro-2-pyridinyl)-1-piperazinyl]-2-(2,5-dimethyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833470-16-9 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2,5-dimethyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-17-0 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

10/719,896


Absolute stereochemistry.



RN 833470-18-1 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-  
[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 833470-19-2 CAPLUS

CN Pyrimidine, 2-(2,5-dimethyl-1-pyrrolidinyl)-4-(4-fluoro-3-methylphenyl)-6-  
[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-23-8 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-piperidinyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 833470-24-9 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-25-0 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-27-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-28-3 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-  
[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 833470-29-4P 833470-31-8P 833470-32-9P  
833470-33-0P 833470-34-1P 833470-35-2P  
833470-36-3P 833470-39-6P 833470-41-0P  
833470-43-2P 833470-46-5P 833470-47-6P  
833470-48-7P 833470-51-2P 833470-52-3P  
833470-55-6P 833470-56-7P 833470-57-8P  
833470-60-3P 833470-62-5P 833470-64-7P  
833470-69-2P 833470-70-5P 833470-71-6P  
833470-72-7P 833470-73-8P 833470-74-9P  
833470-77-2P 833470-79-4P 833470-80-7P  
833470-81-8P 833470-82-9P 833470-83-0P  
833470-84-1P 833470-85-2P 833470-87-4P  
833470-88-5P 833470-91-0P 833470-92-1P  
833470-94-3P 833470-95-4P 833470-96-5P  
833470-97-6P 833470-98-7P 833470-99-8P  
833471-00-4P 833471-03-7P 833471-04-8P  
833471-05-9P 833471-06-0P 833471-09-3P  
833471-10-6P 833471-11-7P 833471-12-8P  
833471-13-9P 833471-14-0P 833471-15-1P

833471-17-3P 833471-18-4P 833471-19-5P  
833471-20-8P 833471-21-9P 833471-22-0P  
833471-26-4P 833471-27-5P 833471-28-6P  
833471-29-7P 833471-30-0P 833471-31-1P  
833471-40-2P 833471-41-3P 833471-43-5P  
833471-44-6P 833471-47-9P 833471-48-0P  
833471-49-1P 833471-50-4P 833471-56-0P  
833471-57-1P 833471-58-2P 833471-62-8P  
833471-63-9P 833471-64-0P 833471-65-1P  
833471-69-5P 833471-70-8P 833471-71-9P  
833471-75-3P 833471-76-4P 833471-77-5P  
833471-79-7P 833471-83-3P 833471-84-4P  
833471-85-5P 833471-86-6P 833471-87-7P  
833471-88-8P 833471-89-9P 833471-90-2P  
833471-91-3P 833471-92-4P 833471-93-5P  
833471-94-6P 833471-95-7P 833471-96-8P  
833471-98-0P 833471-99-1P 833472-00-7P  
833472-01-8P 833472-02-9P 833472-03-0P  
833472-05-2P 833472-08-5P 833472-09-6P  
833472-10-9P 833472-14-3P 833472-17-6P  
833472-20-1P 833472-21-2P 833472-22-3P  
833472-24-5P 833472-25-6P 833472-30-3P  
833472-31-4P 833472-33-6P 833472-34-7P  
833472-36-9P 833472-37-0P 833472-38-1P  
833472-39-2P 833472-41-6P 833472-42-7P  
833472-43-8P 833472-44-9P 833472-47-2P  
833472-48-3P 833472-49-4P 833472-50-7P  
833472-51-8P 833472-52-9P 833472-53-0P  
833472-54-1P 833472-55-2P 833472-56-3P  
833472-57-4P 833472-58-5P 833472-59-6P  
833472-60-9P 833472-61-0P 833472-62-1P  
833472-63-2P 833472-64-3P 833472-65-4P  
833472-66-5P 833472-67-6P 833472-68-7P  
833472-69-8P 833472-70-1P 833472-71-2P  
833472-72-3P 833472-73-4P 833472-74-5P  
833472-75-6P 833472-76-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor  
modulators)

RN 833470-29-4 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-2-methyl-4-[3-  
(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-piperidinyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-31-8 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-32-9 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833470-33-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-34-1 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-piperidinyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-35-2 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-36-3 CAPLUS

CN 3-Pyrrolidinol, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-39-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, (1R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-41-0 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-5-propyl-, (1R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-43-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-46-5 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-47-6 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-48-7 CAPLUS

CN Pyrimidine, 4-(4-fluorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-51-2 CAPLUS

CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-52-3 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-55-6 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-56-7 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-57-8 CAPLUS


CN Pyrimidine, 4-(3,4-difluorophenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833470-60-3 CAPLUS

CN Pyrimidine, 4-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833470-62-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, ethyl ester




10/719,896

(9CI) (CA INDEX NAME)



RN 833470-64-7 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833470-69-2 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-dimethylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-70-5 CAPLUS

CN Pyrimidine, 4-(5-chloro-3-pyridinyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-71-6 CAPLUS

CN Pyrimidine, 4-(5-chloro-3-pyridinyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-72-7 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-dimethylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-73-8 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-methoxy-3-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-74-9 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-methoxy-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833470-77-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3,5-dimethyl-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833470-79-4 CAPLUS


CN Acetamide, N-[6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 833470-80-7 CAPLUS


CN Methanesulfonamide, N-[6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl-3-pyridinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 833470-81-8 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(5-methoxy-3-methyl-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833470-82-9 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3,5-dimethyl-2-pyridinyl)-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 833470-83-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-84-1 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-85-2 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833470-87-4 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 833470-88-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 833470-91-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-4-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833470-92-1 CAPLUS


CN Pyrimidine, 4-[(2R)-4-(3-chloro-4-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833470-94-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833470-95-4 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833470-96-5 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-97-6 CAPLUS

CN Morpholine, 4-[4-(4-chloro-3-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 833470-98-7 CAPLUS


CN Isoquinoline, 1,2,3,4-tetrahydro-2,4,4-trimethyl-7-[2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833470-99-8 CAPLUS

CN Morpholine, 4-[4-(5-chloro-3-pyridinyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-00-4 CAPLUS

CN Pyrimidine, 4-(5-chloro-3-pyridinyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-

10/719,896

methyl-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-03-7 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-04-8 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-05-9 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-06-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833471-09-3 CAPLUS

CN Benzenepropanoic acid, 3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833471-10-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833471-11-7 CAPLUS


CN Benzenepropanol, 3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896



RN 833471-12-8 CAPLUS


CN Benzenepropanamine, N,N-dimethyl-3-[2-(4-morpholinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833471-13-9 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-2-methyl-4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-14-0 CAPLUS

CN Piperazinone, 1-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-4-(3-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)


10/719,896



RN 833471-15-1 CAPLUS

CN Pyrimidine, 4-(5-chloro-3-pyridinyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 833471-17-3 CAPLUS

CN Ethanone, 1-[4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896

RN 833471-18-4 CAPLUS

CN Ethanone, 1-[4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-19-5 CAPLUS

CN Ethanone, 1-[4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-20-8 CAPLUS

CN Benzonitrile, 4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833471-21-9 CAPLUS

CN Benzonitrile, 4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-22-0 CAPLUS

CN Benzonitrile, 4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-26-4 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-6-[4-(1,2,4-oxadiazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-27-5 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-6-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-28-6 CAPLUS

CN Benzoic acid, 4-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-29-7 CAPLUS

CN Benzonitrile, 3-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-30-0 CAPLUS

CN Benzonitrile, 3-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-31-1 CAPLUS

CN Benzonitrile, 3-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-40-2 CAPLUS

CN 3-Pyridinecarbonitrile, 5-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-41-3 CAPLUS

CN 3-Pyridinecarbonitrile, 5-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-43-5 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-44-6 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-pyridinyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833471-47-9 CAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833471-48-0 CAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(2-methyl-1-pyrrolidinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833471-49-1 CAPLUS

CN Ethanone, 1-[3-[6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 833471-50-4 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 833471-56-0 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-6-[(2R)-4-(3-fluoro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833471-57-1 CAPLUS


CN Pyrimidine, 4-(3,4-difluorophenyl)-6-[(2R)-4-(3-fluoro-2-pyridinyl)-2-



10/719,896

methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-58-2 CAPLUS

CN Morpholine, 4-[4-(3,4-difluorophenyl)-6-[(2R)-4-(3-fluoro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-62-8 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-5-methyl-6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/719,896



RN 833471-63-9 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-64-0 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896

RN 833471-65-1 CAPLUS

CN Morpholine, 4-[4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-69-5 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-70-8 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-71-9 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-75-3 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-76-4 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-77-5 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 833471-79-7 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-chloro-6-methoxy-2-pyridinyl)-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833471-83-3 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896

RN 833471-84-4 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-85-5 CAPLUS

CN Morpholine, 4-[4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-86-6 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluoro-3-methylphenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-87-7 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-88-8 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833471-89-9 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-90-2 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-91-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-92-4 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896



RN 833471-93-5 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 833471-94-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-95-7 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-6-[(3R)-4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-2- (9CI) (CA INDEX NAME)

10/719,896

(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N-ethyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833471-96-8 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833471-98-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833471-99-1 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-2-[(2R)-2-methyl-1-piperidinyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 833472-00-7 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-01-8 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-02-9 CAPLUS

CN Morpholine, 4-[4-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-03-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-05-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-08-5 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-09-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833472-10-9 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-14-3 CAPLUS

CN Pyrimidine, 4-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-17-6 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3,5-dichloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-20-1 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-21-2 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-22-3 CAPLUS

CN Morpholine, 4-[4-(4-chloro-3-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-24-5 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-25-6 CAPLUS

CN Morpholine, 4-[4-(4-chloro-3-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-30-3 CAPLUS

CN Pyrimidine, 5-chloro-4-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]-4-pyrimidinyl]-3-methyl-1-piperazinyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-31-4 CAPLUS

CN Pyrimidine, 5-chloro-4-[(3R)-4-[6-(4-fluorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-33-6 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-34-7 CAPLUS

CN 2(1H)-Pyridinone, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-36-9 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(5-chloro-2-methoxy-4-pyrimidinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-37-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-38-1 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-39-2 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833472-41-6 CAPLUS

CN Pyrimidine, 4-(4-chloro-3-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-42-7 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-43-8 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-44-9 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-47-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-48-3 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-49-4 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-50-7 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-51-8 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(2-fluorophenyl)-2-methyl-1-piperazinyl]-2-[(2R)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-52-9 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(2-fluorophenyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-53-0 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(2-fluorophenyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-54-1 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(2-fluorophenyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-55-2 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-56-3 CAPLUS

CN Morpholine, 4-[4-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-57-4 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-58-5 CAPLUS

CN Pyrimidine, 4-(3,4-difluorophenyl)-2-[(2S)-2-methyl-1-pyrrolidinyl]-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833472-59-6 CAPLUS


CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833472-60-9 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-methylphenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-61-0 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-methylphenyl)-6-[(2R)-4-(3-chloro-2-

10/719,896

pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 833472-62-1 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-methylphenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-[(2S)-2-methyl-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-63-2 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833472-64-3 CAPLUS

CN Pyridazine, 3-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 833472-65-4 CAPLUS

CN Pyrimidine, 4-[4-(5-bromo-2-pyrimidinyl)-1-piperazinyl]-6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 833472-66-5 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloropyrazinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-67-6 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-fluoro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-3-methyl-, (3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 833472-68-7 CAPLUS

CN Morpholine, 4-[4-(3-chloro-4-fluorophenyl)-6-[(2S)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-3-methyl-, (3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-69-8 CAPLUS


CN Morpholine, 4-[4-(3,4-difluorophenyl)-6-[(2R)-4-(3-fluoro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-pyrimidinyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833472-70-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[4-[6-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 833472-71-2 CAPLUS

CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(5-chloro-4-pyrimidinyl)-1-

10/719,896


piperazinyl]-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 833472-72-3 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3,6-dichloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-73-4 CAPLUS

CN 2-Pyridinamine, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-74-5 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(5-chloro-4-pyrimidinyl)-2-methyl-1-piperazinyl]-6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833472-75-6 CAPLUS

CN 2,5-Pyridinedicarbonitrile, 6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/719,896



RN 833472-76-7 CAPLUS

CN 2-Pyridinamine, 5-chloro-6-[(3R)-4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-3-methyl-1-piperazinyl]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 833470-66-9 833470-67-0 833470-68-1

833471-45-7 833471-46-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor  
modulators)


RN 833470-66-9 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896



RN 833470-67-0 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 833470-68-1 CAPLUS

CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3-fluoro-4-methylphenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 833471-45-7 CAPLUS

CN Piperazinone, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 833471-46-8 CAPLUS

CN Piperazinone, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-propyl- (9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:1068246 CAPLUS  
DN 142:169085  
TI Syntheses of 2,4,6-trisubstituted pyrimidine derivatives as a new class of  
antifilarial topoisomerase II inhibitors  
AU Katiyar, Sanjay Babu; Bansal, Iti; Saxena, J. K.; Chauhan, P. M. S.  
CS Medicinal and Process Chemistry Division, Central Drug Research Institute,  
Lucknow, 226001, India  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(1), 47-50  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 142:169085  
IT 832076-01-4P 832076-02-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(syntheses of 2,4,6-trisubstituted pyrimidine derivs. as a new class of  
antifilarial topoisomerase II inhibitors)  
RN 832076-01-4 CAPLUS  
CN Morpholine, 4-[4-(4-methyl-1-piperazinyl)-6-(2-thienyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 832076-02-5 CAPLUS  
CN Morpholine, 4-[4-(4-phenyl-1-piperazinyl)-6-(2-thienyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:857162 CAPLUS

DN 141:350185

TI Preparation of pyrimidine derivatives with lysophosphatidic acid  
acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity

IN Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J.  
Peter; Kohm, Cory T.; Tulinsky, John

PA Cell Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 80 pp., which  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204386	A1	20041014	US 2003-671070	20030924
PRAI	US 2002-419694P	P	20021017		
	US 2003-460776P	P	20030404		

OS MARPAT 141:350185


IT 774608-12-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of pyrimidine derivs. with lysophosphatidic acid  
acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)

RN 774608-12-7 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-(5-chloro-2-methylphenyl)-6-[[4-  
(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:686887 CAPLUS

DN 142:198005

TI Two directions of the reaction of 4-bromobenzaldehyde with substituted acetophenones and urea. Synthesis of aryl-substituted pyrimidin-2-one and hexahydropyrimido[4,5-d]pyrimidin-2,7-dione

AU Sedova, V. F.; Shkurko, O. P.

CS Siberian Branch of the Russian Academy of Sciences, N. N. Vorozhstsov  
Novosibirsk Institute of Organic Chemistry, Novosibirsk, 630090, Russia

SO Chemistry of Heterocyclic Compounds (New York, NY, United  
States) (Translation of Khimiya Geterotsiklicheskih Soedinenii) (2004),  
40(2), 194-202

CODEN: CHCCAL; ISSN: 0009-3122

PB Kluwer Academic/Consultants Bureau

DT Journal

LA English


OS CASREACT 142:198005

IT 413591-67-0P 681447-48-3P 835925-42-3P  
835925-43-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of arylpyrimidin-2-ones and arylhexahydropyrimido[4,5-  
d]pyrimidine-2,7-diones from 4-bromobenzaldehyde, acetophenones and  
urea)


RN 413591-67-0 CAPLUS

CN Pyrimidine, 4-(4-bromophenyl)-6-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX  
NAME)



RN 681447-48-3 CAPLUS


CN Pyrimidine, 4-(4-bromophenyl)-6-(4-methylphenyl)-2-(1-piperidinyl)- (9CI)  
(CA INDEX NAME)



RN 835925-42-3 CAPLUS


CN Pyrimidine, 4-(4-bromophenyl)-6-(4-butylphenyl)-2-(1-piperidinyl)- (9CI)  
(CA INDEX NAME)

10/719,896



RN 835925-43-4 CAPLUS

CN Pyrimidine, 5-bromo-4-(4-bromophenyl)-6-phenyl-2-(1-piperidinyl)- (9CI)  
(CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:467883 CAPLUS  
 DN 141:38627  
 TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol  
 (pi) 3-kinase inhibitors and their use in the treatment of cancer  
 IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048365	A1	20040610	WO 2003-US37294	20031121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507100	A1	20040610	CA 2003-2507100	20031121
	AU 2003295776	A1	20040618	AU 2003-295776	20031121
	US 2004176385	A1	20040909	US 2003-719896	20031121
	EP 1575940	A1	20050921	EP 2003-786980	20031121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016485	A	20051011	BR 2003-16485	20031121
	CN 1735607	A	20060215	CN 2003-80108239	20031121
	JP 2006514118	T	20060427	JP 2005-510381	20031121
	NO 2005002927	A	20050708	NO 2005-2927	20050615
	IN 2005KN01189	A	20060609	IN 2005-KN1189	20050621
PRAI	US 2002-428473P	P	20021121		
	US 2003-438568P	P	20030107		
	US 2003-523081P	P	20031119		
	WO 2003-US37294	W	20031121		
OS	MARPAT 141:38627				
IT	701242-64-0P, 3-[6-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701242-65-1P, N-[6-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-6-amine 701242-66-2P, 4-(3-Hydroxyphenyl)-6-[(1H-indazol-5-yl)amino]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-67-3P, 4-[3-(2-Hydroxyethoxy)phenyl]-6-[(1H-indazol-5-yl)amino]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-68-4P, 4-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)-6-(4-phenoxyphenyl)pyrimidine-5-carboxylic acid 701242-69-5P, 4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-6-[(1H-indazol-5-yl)amino]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-70-8P, 4-(1H-Indazol-5-ylamino)-6-[4-(methylsulfonyl)phenyl]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-71-9P, 4-[3-[(4-tert-Butylphenyl)oxy]phenyl]-6-[(1H-indazol-5-yl)amino]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-72-0P, 4-[3-(3,5-Dichlorophenoxy)phenyl]-6-[(1H-indazol-5-yl)amino]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-73-1P, 4-(4-tert-Butylphenyl)-6-[(1H-indazol-5-yl)amino]-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701242-74-2P, 4-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)-6-phenylpyrimidine-5-carboxylic acid 701242-75-3P, N-[6-(4-Methoxy-3-methylphenyl)-2-				

(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-76-4P,  
2-[3-[6-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenoxy]ethanol 701242-77-5P, N-[2-(Morpholin-4-yl)-6-(4-phenoxyphenyl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-78-6P,  
N-[6-[4-(Methylsulfonyl)phenyl]-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-79-7P, N-[6-[3-[(4-tert-Butylphenyl)oxy]phenyl]-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-80-0P, N-[6-[3-(3,5-Dichlorophenoxy)phenyl]-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-81-1P,  
N-[6-(4-tert-Butylphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-82-2P, N-[2-(Morpholin-4-yl)-6-phenylpyrimidin-4-yl]-1H-indazol-5-amine 701242-83-3P, 4-[6-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701242-84-4P,  
N-[6-(3-Fluorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-85-5P, N-[6-(4-Fluorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-86-6P, N-[6-(2-Fluorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-87-7P,  
N-[6-(3-Chlorophenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-88-8P, N-[2-(Morpholin-4-yl)-6-(3-nitrophenyl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-89-9P, N-[2-(Morpholin-4-yl)-6-[3-(trifluoromethoxy)phenyl]pyrimidin-4-yl]-1H-indazol-5-amine 701242-90-2P, N-[2-(Morpholin-4-yl)-6-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl]-1H-indazol-5-amine 701242-91-3P, N-[6-[3-(Benzoyloxy)phenyl]-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-92-4P,  
N-[6-(3-Ethoxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-93-5P, 3-[6-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]benzonitrile 701242-94-6P,  
N-[6-(3-Methylphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-amine 701242-95-7P, Ethyl 4-[4-(3-hydroxyphenyl)-6-[(1H-indazol-5-yl)amino]pyrimidin-2-yl]piperazine-1-carboxylate 701242-96-8P,  
3-[2-(4-Acetyl)piperazin-1-yl]-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol 701242-97-9P, 3-[6-[(1-Acetyl-2,3-dihydro-1H-indol-6-yl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701242-98-0P,  
3-[6-[(2,3-Dihydro-1H-inden-5-yl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701242-99-1P, 3-[6-(9H-Fluoren-2-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-00-7P, 3-[6-(2,3-Dihydro-1,4-benzodioxin-6-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-01-8P, 3-[6-[(3,4-Dimethoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-02-9P, 3-[6-[(2,3-Dihydro-1H-indol-6-yl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-03-0P, 3-[6-(1H-Indazol-6-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-04-1P, 3-[6-(1,3-Benzodioxol-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-05-2P,  
3-[6-[(3-Chloro-4-methoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-06-3P, 5-[6-(3-Hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]-2-methoxyphenol 701243-07-4P,  
3-[6-[(3-Fluoro-4-methoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-08-5P, 5-[6-(3-Hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]-1,3-dihydro-2H-benzimidazol-2-one 701243-09-6P, 3-[6-[(3,4-Dimethylphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-10-9P, 3-[2-(Morpholin-4-yl)-6-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-11-0P,  
4-[6-(3-Hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]-2-nitrophenol 701243-12-1P, 2-Chloro-4-[6-(3-hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]phenol 701243-14-3P,  
3-[2-(Azepan-1-yl)-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol 701243-15-4P, 3-[2-(1,4-Diazepan-1-yl)-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol 701243-16-5P,  
3-[2-((2R,6S)-2,6-Dimethylmorpholin-4-yl)-6-(1H-indazol-5-ylamino)pyrimidin-4-yl]phenol 701243-17-6P, 3-[6-(1H-Indazol-5-



ylamino)-2-(4-thiomorpholinyl)pyrimidin-4-yl]phenol 701243-18-7P  
 , N-[6-(3-Methoxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]-1H-indazol-5-  
 amine 701243-21-2P, 3-[6-[(6-Methoxypyridin-3-yl)amino]-2-  
 (morpholin-4-yl)pyrimidin-4-yl]phenol 701243-22-3P,  
 3-[2-(Morpholin-4-yl)-6-[(pyridin-3-yl)amino]pyrimidin-4-yl]phenol  
 701243-26-7P, 3-[6-Anilino-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-27-8P, 3-[2-(Morpholin-4-yl)-6-[(3,4,5-  
 trimethoxyphenyl)amino]pyrimidin-4-yl]phenol 701243-28-9P,  
 3-[6-[(4-Butoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-29-0P, 3-[2-(Morpholin-4-yl)-6-[[4-  
 (pentyloxy)phenyl]amino]pyrimidin-4-yl]phenol 701243-30-3P,  
 3-[6-[[4-(Hexyloxy)phenyl]amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-31-4P, 3-[6-(1H-Benzimidazol-6-ylamino)-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-32-5P, 4-[4-(3-Hydroxyphenyl)-6-  
 [(1H-indazol-5-yl)amino]pyrimidin-2-yl]piperazine-1-carboxaldehyde  
 701243-33-6P, Methyl 3-[6-(1H-indazol-5-ylamino)-2-(morpholin-4-  
 yl)pyrimidin-4-yl]benzoate 701243-34-7P,  
 4-[4-(3-Methoxyphenyl)-6-(morpholin-4-yl)pyrimidin-2-yl]morpholine  
 701243-35-8P, 2-[6-(1H-Indazol-5-ylamino)-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-39-2P, 3-[6-[2-  
 (Hydroxymethyl)pyrrolidin-1-yl]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-40-5P, 3-[6-[(3-Aminocyclohexyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-41-6P, 3-[6-[(1R,2R)-2-  
 Aminocyclohexyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-42-7P, 3-[6-[(4-Hydroxycyclohexyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-43-8P, 1-[6-(3-Hydroxyphenyl)-2-  
 (morpholin-4-yl)pyrimidin-4-yl]piperidin-4-ol 701243-44-9P,  
 3-[6-((3R,5S)-3,5-Dimethylmorpholin-4-yl)-2-(morpholin-4-yl)pyrimidin-4-  
 yl]phenol 701243-45-0P, 3-[2-(Morpholin-4-yl)-6-[4-(4-  
 nitrophenyl)piperazin-1-yl]pyrimidin-4-yl]phenol 701243-46-1P,  
 3-[6-[4-(3-Chlorophenyl)piperazin-1-yl]-2-(morpholin-4-yl)pyrimidin-4-  
 yl]phenol 701243-47-2P, 3-[6-[4-(1,3-Benzodioxol-5-  
 ylmethyl)piperazin-1-yl]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-48-3P, 3-[2-(Morpholin-4-yl)-6-[4-(pyridin-2-yl)piperazin-1-  
 yl]pyrimidin-4-yl]phenol 701243-49-4P, 3-[6-(4-Acetylpiperazin-1-  
 yl)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-50-7P,  
 3-[6-(1,4-Diazepan-1-yl)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-51-8P, 3-[6-(4-Methyl-1,4-diazepan-1-yl)-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-60-9P, 3-[6-[(2-  
 Methoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-61-0P, 3-[6-[(3-Methoxyphenyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-62-1P, 3-[6-[(4-  
 Methoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-63-2P, 3-[6-[(2,4-Dimethoxyphenyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-64-3P, 3-[6-[(2,5-  
 Dimethoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-65-4P, 3-[6-[(2,3-Dimethoxyphenyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-66-5P, 3-[6-[(2-  
 Ethoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-67-6P, 3-[6-[(4-Ethoxyphenyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-68-7P, 3-[6-[(2,5-  
 Diethoxyphenyl)amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-69-8P, 3-[6-[(2-Methoxy-6-methylphenyl)amino]-2-(morpholin-  
 4-yl)pyrimidin-4-yl]phenol 701243-70-1P, 3-[2-(Morpholin-4-yl)-6-  
 [(3-phenoxyphenyl)amino]pyrimidin-4-yl]phenol 701243-71-2P,  
 3-[2-(Morpholin-4-yl)-6-[(4-phenoxyphenyl)amino]pyrimidin-4-yl]phenol  
 701243-72-3P, 3-[6-[(3-(Benzyloxy)phenyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-73-4P 701243-74-5P,  
 2-[6-(3-Hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-ylamino]phenol  
 701243-75-6P, 3-[6-[(3-Hydroxyphenyl)amino]-2-(morpholin-4-  
 yl)pyrimidin-4-yl]phenol 701243-76-7P, 3-[6-[(4-

Hydroxyphenyl] amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-77-8P, 4-Chloro-2-[[6-(3-hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]phenol 701243-78-9P,  
 3-[[6-(3-Hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]-1,1'-biphenyl-4-ol 701243-79-0P, 3-[6-[(4-Anilino-2-methoxyphenyl) amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol  
 701243-80-3P, 3-[6-[(1-Ethyl-2-methyl-1H-benzimidazol-5-yl) amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-81-4P,  
 N-[4-Ethoxy-3-[[6-(3-hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]phenyl]acetamide 701243-82-5P, 2-Methoxy-5-[[2-(morpholin-4-yl)-6-phenylpyrimidin-4-yl]amino]phenol 701243-84-7P,  
 N-[2-(Morpholin-4-yl)-6-[3-[2-(piperidin-1-yl)ethoxy]phenyl]pyrimidin-4-yl]-1H-indazol-5-amine 701243-85-8P, 4-(3-Methoxyphenyl)-2-(morpholin-4-yl)-6-[(pyridin-3-yl)amino]pyrimidine-5-carboxylic acid  
 701243-86-9P, 3-[6-[4-(3-Methoxyphenyl)piperazin-1-yl]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-87-0P,  
 3-[2-(Morpholin-4-yl)-6-[4-[2-(morpholin-4-yl)-2-oxoethyl]piperazin-1-yl]pyrimidin-4-yl]phenol 701243-88-1P, 3-[2-(Morpholin-4-yl)-6-[4-(1-phenylethyl)piperazin-1-yl]pyrimidin-4-yl]phenol  
 701243-89-2P, 3-[2-(Morpholin-4-yl)-6-[4-(2-phenylethyl)piperazin-1-yl]pyrimidin-4-yl]phenol 701243-90-5P, 3-[6-[4-[2-(Dimethylamino)ethyl]piperazin-1-yl]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-91-6P, 3-[6-[(3,4-Dihydro-2H-1,5-benzodioxepin-7-yl) amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-92-7P,  
 3-[6-[[3-(Cyclopentyloxy)-4-methoxyphenyl] amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701243-93-8P, 3-[6-(1H-Indazol-5-ylamino)-2-(1-oxido-4-thiomorpholinyl)pyrimidin-4-yl]phenol  
 701243-94-9P, 3-[2-(2,6-Dimethylmorpholin-4-yl)-6-[(1H-indazol-5-yl) amino]pyrimidin-4-yl]phenol 701243-95-0P,  
 5-[[6-(3-Hydroxyphenyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino]pyridin-2-ol 701243-96-1P, 6-(3-Fluorophenyl)-2-(morpholin-4-yl)-N-pyridin-3-ylpyrimidin-4-amine 701243-97-2P, 2-(Morpholin-4-yl)-N-pyridin-3-yl-6-[3-(trifluoromethyl)phenyl]pyrimidin-4-amine 701243-98-3P,  
 6-(3-Methoxyphenyl)-2-(morpholin-4-yl)-N-pyridin-3-ylpyrimidin-4-amine 701243-99-4P, 3-[2-(Morpholin-4-yl)-6-[(pyrimidin-2-yl) amino]pyrimidin-4-yl]phenol 701244-00-0P,  
 3-[2-(Morpholin-4-yl)-6-[(pyrazin-2-yl) amino]pyrimidin-4-yl]phenol 701244-01-1P, 3-[6-(Isoquinolin-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol 701244-02-2P, 3-[2-(Morpholin-4-yl)-6-[(quinolin-6-yl) amino]pyrimidin-4-yl]phenol 701244-03-3P,  
 3-[2-(Morpholin-4-yl)-6-[(quinolin-3-yl) amino]pyrimidin-4-yl]phenol 701244-04-4P, 3-[2-(Morpholin-4-yl)-6-[(pyridin-2-yl) amino]pyrimidin-4-yl]phenol 701244-05-5P 701244-06-6P,  
 3-[2-(Morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenyl acetate 701244-07-7P, 3-[2-(Morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenyl pivalate 701244-08-8P,  
 3-[2-(Morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenyl 2-methylpropanoate 701244-09-9P, 6-(3-Aminophenyl)-2-(morpholin-4-yl)-N-pyridin-3-ylpyrimidin-4-amine 701244-10-2P,  
 2-Fluoro-3-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenol 701244-11-3P 701244-12-4P,  
 2-Chloro-5-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenol 701244-13-5P, N-[3-[2-(Morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenyl]methanesulfonamide 701244-14-6P,  
 4-Fluoro-3-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenol 701244-15-7P, 4-Bromo-3-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenol 701244-16-8P,  
 2-Methyl-5-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenol 701244-17-9P, Methyl 3-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-yl]phenyl carbonate 701244-18-0P,  
 4-Methyl-3-[2-(morpholin-4-yl)-6-[(pyridin-3-yl) amino]pyrimidin-4-

10/719,896


yl]phenol 701244-20-4P, 4-(1H-Indazol-5-ylamino)-6-(4-methoxy-3-methylphenyl)-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 701244-24-8P, 3-[6-(1H-Indazol-5-ylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol bistrifluoroacetate 701244-28-2P, 3-[2-Morpholin-4-yl-6-(3-pyridinylamino)pyrimidin-4-yl]phenol dihydrochloride 701244-29-3P 701244-30-6P 701244-31-7P 701244-32-8P 701255-46-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)


RN 701242-64-0 CAPLUS

CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-65-1 CAPLUS


CN 1H-Indazol-6-amine, N-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-66-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3-hydroxyphenyl)-6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-67-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[3-(2-hydroxyethoxy)phenyl]-6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 701242-68-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 701242-69-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-70-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(1H-indazol-5-ylamino)-6-[4-(methanesulfonyl)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 701242-71-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[3-[4-(1,1-dimethylethyl)phenoxy]phenyl]-6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 701242-72-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[3-(3,5-dichlorophenoxy)phenyl]-6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-73-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4-(1,1-dimethylethyl)phenyl]-6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 701242-74-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 701242-75-3 CAPLUS


CN 1H-Indazol-5-amine, N-[6-(4-methoxy-3-methylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-76-4 CAPLUS

CN Ethanol, 2-[3-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 701242-77-5 CAPLUS


CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-(4-phenoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-78-6 CAPLUS


CN 1H-Indazol-5-amine, N-[6-[4-(methylsulfonyl)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-79-7 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[3-[4-(1,1-dimethylethyl)phenoxy]phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-80-0 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[3-(3,5-dichlorophenoxy)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701242-81-1 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[4-(1,1-dimethylethyl)phenyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/719,896




RN 701242-82-2 CAPLUS

CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-phenyl-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 701242-83-3 CAPLUS


CN Phenol, 4-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701242-84-4 CAPLUS


CN 1H-Indazol-5-amine, N-[6-(3-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 701242-85-5 CAPLUS

CN 1H-Indazol-5-amine, N-[6-(4-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701242-86-6 CAPLUS


CN 1H-Indazol-5-amine, N-[6-(2-fluorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701242-87-7 CAPLUS


CN 1H-Indazol-5-amine, N-[6-(3-chlorophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 701242-88-8 CAPLUS

CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-(3-nitrophenyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701242-89-9 CAPLUS


CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-90-2 CAPLUS


CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-91-3 CAPLUS

CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-92-4 CAPLUS


CN 1H-Indazol-5-amine, N-[6-(3-ethoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-93-5 CAPLUS


CN Benzonitrile, 3-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-94-6 CAPLUS

CN 1H-Indazol-5-amine, N-[6-(3-methylphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701242-95-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-(3-hydroxyphenyl)-6-(1H-indazol-5-ylamino)-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 701242-96-8 CAPLUS


CN Piperazine, 1-acetyl-4-[4-(3-hydroxyphenyl)-6-(1H-indazol-5-ylamino)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701242-97-9 CAPLUS

CN 1H-Indol-6-amine, 1-acetyl-2,3-dihydro-N-[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-98-0 CAPLUS


CN Phenol, 3-[6-[(2,3-dihydro-1H-inden-5-yl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701242-99-1 CAPLUS


CN Phenol, 3-[6-(9H-fluoren-2-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-00-7 CAPLUS

CN Phenol, 3-[6-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-01-8 CAPLUS

CN Phenol, 3-[6-[(3,4-dimethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-02-9 CAPLUS


CN Phenol, 3-[6-[(2,3-dihydro-1H-indol-6-yl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 701243-03-0 CAPLUS

CN Phenol, 3-[6-(1H-indazol-6-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 701243-04-1 CAPLUS

CN Phenol, 3-[6-(1,3-benzodioxol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-05-2 CAPLUS

CN Phenol, 3-[6-[(3-chloro-4-methoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 701243-06-3 CAPLUS

CN Phenol, 5-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinylamino]-2-methoxy-  
(9CI) (CA INDEX NAME)




10/719,896




RN 701243-07-4 CAPLUS

CN Phenol, 3-[6-[(3-fluoro-4-methoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-08-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 701243-09-6 CAPLUS


CN Phenol, 3-[6-[(3,4-dimethylphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 701243-10-9 CAPLUS

CN Phenol, 3-(2,6-di-4-morpholinyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME).




RN 701243-11-0 CAPLUS

CN Phenol, 4-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]-2-nitro- (9CI) (CA INDEX NAME)



RN 701243-12-1 CAPLUS


CN Phenol, 2-chloro-4-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 701243-14-3 CAPLUS


CN Phenol, 3-[2-(hexahydro-1H-azepin-1-yl)-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896



RN 701243-15-4 CAPLUS


CN Phenol, 3-[2-(hexahydro-1H-1,4-diazepin-1-yl)-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-16-5 CAPLUS

CN Phenol, 3-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 701243-17-6 CAPLUS


CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-(4-thiomorpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-18-7 CAPLUS

CN 1H-Indazol-5-amine, N-[6-(3-methoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-21-2 CAPLUS


CN Phenol, 3-[6-[(6-methoxy-3-pyridinyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-22-3 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-26-7 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-27-8 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-28-9 CAPLUS

CN Phenol, 3-[6-[(4-butoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-29-0 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[[4-(pentyloxy)phenyl]amino]-4-pyrimidinyl]-


10/719,896

(9CI) (CA INDEX NAME)




RN 701243-30-3 CAPLUS

CN Phenol, 3-[6-[[4-(hexyloxy)phenyl]amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-31-4 CAPLUS


CN Phenol, 3-[6-(1H-benzimidazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-32-5 CAPLUS


CN 1-Piperazinecarboxaldehyde, 4-[4-(3-hydroxyphenyl)-6-(1H-indazol-5-ylamino)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-33-6 CAPLUS

CN Benzoic acid, 3-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 701243-34-7 CAPLUS


CN Morpholine, 4,4'-[6-(3-methoxyphenyl)-2,4-pyrimidinediyl]bis- (9CI) (CA INDEX NAME)



RN 701243-35-8 CAPLUS


CN Phenol, 2-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-39-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-40-5 CAPLUS

CN Phenol, 3-[6-[(3-aminocyclohexyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-41-6 CAPLUS

CN Phenol, 3-[6-[[ (1R,2R)-2-aminocyclohexyl]amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/719,896




RN 701243-42-7 CAPLUS

CN Phenol, 3-[6-[(4-hydroxycyclohexyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-43-8 CAPLUS

CN 4-Piperidinol, 1-[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 701243-44-9 CAPLUS

CN Phenol, 3-[6-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/719,896




RN 701243-45-0 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[4-(4-nitrophenyl)-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-46-1 CAPLUS


CN Phenol, 3-[6-[4-(3-chlorophenyl)-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-47-2 CAPLUS


CN Phenol, 3-[6-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-48-3 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-49-4 CAPLUS


CN Piperazine, 1-acetyl-4-[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-50-7 CAPLUS


CN Phenol, 3-[6-(hexahydro-1H-1,4-diazepin-1-yl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-51-8 CAPLUS

CN Phenol, 3-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-60-9 CAPLUS

CN Phenol, 3-[6-[(2-methoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-61-0 CAPLUS


CN Phenol, 3-[6-[(3-methoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 701243-62-1 CAPLUS

CN Phenol, 3-[6-[(4-methoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 701243-63-2 CAPLUS

CN Phenol, 3-[6-[(2,4-dimethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-64-3 CAPLUS


CN Phenol, 3-[6-[(2,5-dimethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-65-4 CAPLUS


CN Phenol, 3-[6-[(2,3-dimethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 701243-66-5 CAPLUS

CN Phenol, 3-[6-[(2-ethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-67-6 CAPLUS


CN Phenol, 3-[6-[(4-ethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-68-7 CAPLUS


CN Phenol, 3-[6-[(2,5-diethoxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 701243-69-8 CAPLUS

CN Phenol, 3-[6-[(2-methoxy-6-methylphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-70-1 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-[(3-phenoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-71-2 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-[(4-phenoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-72-3 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-73-4 CAPLUS

CN Phenol, 3-[6-[[4-methoxy-3-dibenzofuranyl]amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-74-5 CAPLUS

CN Phenol, 2-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]-6-methoxy-3-dibenzofuran (9CI) (CA INDEX NAME)






10/719,896


RN 701243-75-6 CAPLUS

CN Phenol, 3-[6-[(3-hydroxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 701243-76-7 CAPLUS

CN Phenol, 3-[6-[(4-hydroxyphenyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701243-77-8 CAPLUS


CN Phenol, 4-chloro-2-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)



RN 701243-78-9 CAPLUS


CN [1,1'-Biphenyl]-4-ol, 3-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 701243-79-0 CAPLUS

CN Phenol, 3-[6-[[2-methoxy-4-(phenylamino)phenyl]amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-80-3 CAPLUS


CN Phenol, 3-[6-[[1-ethyl-2-methyl-1H-benzimidazol-5-yl]amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-81-4 CAPLUS


CN Acetamide, N-[4-ethoxy-3-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-82-5 CAPLUS

CN Phenol, 2-methoxy-5-[[2-(4-morpholinyl)-6-phenyl-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)



RN 701243-84-7 CAPLUS


CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-[3-[2-(1-piperidinyl)ethoxy]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-85-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3-methoxyphenyl)-2-(4-morpholinyl)-6-(3-pyridinylamino)- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-86-9 CAPLUS

CN Phenol, 3-[6-[4-(3-methoxyphenyl)-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-87-0 CAPLUS

CN Morpholine, 4-[[4-[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 701243-88-1 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-[4-(1-phenylethyl)-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/719,896


RN 701243-89-2 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[4-(2-phenylethyl)-1-piperazinyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-90-5 CAPLUS

CN Phenol, 3-[6-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-91-6 CAPLUS


CN Phenol, 3-[6-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-92-7 CAPLUS


CN Phenol, 3-[6-[[3-(cyclopentyloxy)-4-methoxyphenyl]amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-93-8 CAPLUS

CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-(1-oxido-4-thiomorpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-94-9 CAPLUS


CN Phenol, 3-[2-(2,6-dimethyl-4-morpholinyl)-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-95-0 CAPLUS


CN 2(1H)-Pyridinone, 5-[[6-(3-hydroxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/719,896




RN 701243-96-1 CAPLUS

CN 4-Pyrimidinamine, 6-(3-fluorophenyl)-2-(4-morpholinyl)-N-3-pyridinyl-  
(9CI) (CA INDEX NAME)




RN 701243-97-2 CAPLUS

CN 4-Pyrimidinamine, 2-(4-morpholinyl)-N-3-pyridinyl-6-[3-  
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 701243-98-3 CAPLUS


CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-2-(4-morpholinyl)-N-3-pyridinyl-  
(9CI) (CA INDEX NAME)



10/719,896

RN 701243-99-4 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-(2-pyrimidinylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 701244-00-0 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-(pyrazinylamino)-4-pyrimidinyl]- (9CI) (CA  
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 701244-01-1 CAPLUS

CN Phenol, 3-[6-(5-isoquinolinylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 701244-02-2 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-(6-quinolinylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




10/719,896




RN 701244-03-3 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-(3-quinolinylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 701244-04-4 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-(2-pyridinylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 701244-05-5 CAPLUS


CN Butanoic acid, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



10/719,896


RN 701244-06-6 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 701244-07-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 701244-08-8 CAPLUS


CN Propanoic acid, 2-methyl-, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 701244-09-9 CAPLUS


CN 4-Pyrimidinamine, 6-(3-aminophenyl)-2-(4-morpholinyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)

10/719,896



RN 701244-10-2 CAPLUS


CN Phenol, 2-fluoro-3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701244-11-3 CAPLUS

CN L-Valine, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]phenyl  
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 701244-12-4 CAPLUS


CN Phenol, 2-chloro-5-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 701244-13-5 CAPLUS

CN Methanesulfonamide, N-[3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 701244-14-6 CAPLUS


CN Phenol, 4-fluoro-3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701244-15-7 CAPLUS


CN Phenol, 4-bromo-3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701244-16-8 CAPLUS

CN Phenol, 2-methyl-5-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701244-17-9 CAPLUS


CN Carbonic acid, methyl 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-  
pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 701244-18-0 CAPLUS


CN Phenol, 4-methyl-3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896



RN 701244-20-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(1H-indazol-5-ylamino)-6-(4-methoxy-3-methylphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 701244-24-8 CAPLUS

CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 701242-64-0

CMF C21 H20 N6 O2




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/719,896



RN 701244-28-2 CAPLUS


CN Phenol, 3-[2-(4-morpholinyl)-6-(3-pyridinylamino)-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 701244-29-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-6-(3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 701244-30-6 CAPLUS


CN 1H-Indazol-5-amine, N-[2-(4-morpholinyl)-6-(3-quinolinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 701244-31-7 CAPLUS

CN 1H-Indazol-5-amine, N-[6-(3-bromophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 701244-32-8 CAPLUS

CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-,  
hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 701255-46-1 CAPLUS

CN Phenol, 3-[6-(1H-benzotriazol-5-ylamino)-2-(4-morpholinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



10/719,896




IT 701244-27-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)

RN 701244-27-1 CAPLUS

CN 4-Pyrimidinamine, 2-(4-morpholinyl)-6-[3-(phenylmethoxy)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:353186 CAPLUS

DN 140:375177

TI Preparation of melanocortin-4 receptor binding compounds

IN Vos, Tricia J.; Solomon, Michael E.; Claiborne, Christopher F.; Maguire, Martin P.; Dai, Mingshi; Patane, Michael; Marsilje, Thomas H.

PA Millennium Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of U.S. 6,699,873.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004082779	A1	20040429	US 2003-462436	20030616
	US 6699873	B1	20040302	US 2001-778468	20010207
	CA 2529445	A1	20051222	CA 2004-2529445	20040615
	WO 2005121100	A1	20051222	WO 2004-US19124	20040615
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004320025	A1	20060119	AU 2004-320025	20040615
	EP 1644337	A1	20060412	EP 2004-776621	20040615
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006527776	T	20061207	JP 2006-521070	20040615
PRAI	US 1999-147288P	P	19990804		
	US 2000-223277P	P	20000803		
	US 2000-632309	B2	20000804		
	US 2001-778468	A2	20010207		
	US 2003-462436	A	20030616		
	WO 2004-US19124	W	20040615		
OS	MARPAT 140:375177				
IT	326481-01-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(target compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)				
RN	326481-01-0 CAPLUS				
CN	Pyrimidine, 4-(4-methylphenyl)-6-phenyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)				

10/719,896



10/719,896

L4 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:331897 CAPLUS

DN 140:350578

TI Small organic compounds for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL

IN Nieland, Thomas J. F.; Krieger, Monty; Kirchhausen, Tomas

PA Massachusetts Institute of Technology, USA; Center for Blood Research, Inc.

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004032716	A2	20040422	WO 2003-US31918	20031008
	WO 2004032716	A9	20040819		
	WO 2004032716	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2501685	A1	20040422	CA 2003-2501685	20031008
----	---------	----	----------	-----------------	----------

AU	2003288925	A1	20040504	AU 2003-288925	20031008
----	------------	----	----------	----------------	----------

US	2004171073	A1	20040902	US 2003-681746	20031008
----	------------	----	----------	----------------	----------

EP	1562605	A2	20050817	EP 2003-781314	20031008
----	---------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP	2006515274	T	20060525	JP 2004-543548	20031008
----	------------	---	----------	----------------	----------

PRAI	US 2002-417083P	P	20021008		
------	-----------------	---	----------	--	--

WO	2003-US31918	W	20031008		
----	--------------	---	----------	--	--

IT 302605-23-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)


RN 302605-23-8 CAPLUS

CN Morpholine, 4-[4-(4-bromophenyl)-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:204251 CAPLUS  
DN 141:260674  
TI A facile one-pot microwave-assisted conversion of 3',5'-dibromo/diiodo-4'-hydroxy substituted chalcones to 2-substituted 4,6-diarylpyrimidines using S-benzylisothiuronium chloride (SBT) and their antibacterial activities  
AU Gahlot, Udaibhan S.; Rao, Surendra S.; Dulawat, Shiv S.; Ameta, K. L.; Verma, B. L.  
CS Department of Chemistry, B.N. (P.G.) College, M.L.S. University, Udaipur, 313002, India  
SO Afinidad (2003), 60(508), 558-562  
CODEN: AFINAE; ISSN: 0001-9704  
PB Asociacion de Quimicos e Ingenieros del Instituto Quimico de Sarria  
DT Journal  
LA English  
OS CASREACT 141:260674  
IT 245055-74-7P 245055-75-8P 756494-96-9P  
756494-97-0P 756494-98-1P 756494-99-2P  
756495-00-8P 756495-01-9P 756495-02-0P  
756495-03-1P 756495-04-2P 756495-05-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(microwave-assisted heterocyclization of chalcones with S-benzylisothiuronium chloride and antibacterial activity of the pyrimidinylphenols formed)  
RN 245055-74-7 CAPLUS  
CN Phenol, 2,6-dibromo-4-[6-phenyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 245055-75-8 CAPLUS  
CN Phenol, 2,6-dibromo-4-[6-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 756494-96-9 CAPLUS  
CN Phenol, 2,6-dibromo-4-[6-[4-(dimethylamino)phenyl]-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 756494-97-0 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-(4-nitrophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 756494-98-1 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 756494-99-2 CAPLUS


CN Phenol, 2,6-dibromo-4-[6-(3-nitrophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 756495-00-8 CAPLUS


CN Phenol, 2,6-diiodo-4-[6-phenyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)

10/719,896




RN 756495-01-9 CAPLUS

CN Phenol, 2,6-diiodo-4-[6-(3-nitrophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 756495-02-0 CAPLUS

CN Phenol, 4-[6-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-2,6-diiodo-  
(9CI) (CA INDEX NAME)



RN 756495-03-1 CAPLUS


CN Phenol, 4-[6-[4-(dimethylamino)phenyl]-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
2,6-diiodo- (9CI) (CA INDEX NAME)



RN 756495-04-2 CAPLUS


CN Phenol, 2,6-diiodo-4-[6-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-4-  
pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896



RN 756495-05-3 CAPLUS

CN Phenol, 2,6-diiodo-4-[6-(4-nitrophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/719,896

L4 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:176560 CAPLUS

DN 140:217656

TI Preparation of aryl-substituted tetrahydropyrimidines and related compounds as melanocortin-4 receptor binding compounds

IN Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.

PA Millennium Pharmaceuticals, Inc., USA

SO U.S., 216 pp., Cont.-in-part of U.S. Ser. No. 632309.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6699873	B1	20040302	US 2001-778468	20010207
	WO 2002062766	A2	20020815	WO 2002-US3566	20020207
	WO 2002062766	A3	20021003		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1363890	A2	20031126	EP 2002-718920	20020207
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004082779	A1	20040429	US 2003-462436	20030616
PRAI	US 1999-147288P	P	19990804		
	US 2000-223277P	P	20000803		
	US 2000-632309	A2	20000804		
	US 2001-778468	A	20010207		
	WO 2002-US3566	W	20020207		
OS	MARPAT 140:217656				
IT	326481-01-0P, 4-Phenyl-2-piperazin-1-yl-6-p-tolyl-pyrimidine				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)				
RN	326481-01-0 CAPLUS				
CN	Pyrimidine, 4-(4-methylphenyl)-6-phenyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)				




10/719,896


RE.CNT 10      THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896


L4 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:973238 CAPLUS  
DN 140:357287  
TI Base catalysed pyrimidine synthesis using microwave  
AU Kidwai, M.; Rastogi, S.; Saxena, S.  
CS Department of Chemistry, University of Delhi, Delhi, 110007, India  
SO Bulletin of the Korean Chemical Society (2003), 24(11), 1575-1578  
CODEN: BKCSDE; ISSN: 0253-2964  
PB Korean Chemical Society  
DT Journal  
LA English  
OS CASREACT 140:357287  
IT 22539-53-3P 260445-96-3P 260446-05-7P  
681809-41-6P 681809-43-8P 681809-44-9P  
681809-46-1P 681809-48-3P 681809-50-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrimidines via a microwave assisted basic alumina catalyzed  
condensation)  
RN 22539-53-3 CAPLUS  
CN Pyrimidine, 4,6-diphenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 260445-96-3 CAPLUS  
CN Morpholine, 4-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 260446-05-7 CAPLUS  
CN Pyrimidine, 4,6-diphenyl-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 681809-41-6 CAPLUS  
CN Morpholine, 4-[4-(1,3-benzodioxol-5-yl)-6-(4-bromophenyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

10/719,896




RN 681809-43-8 CAPLUS

CN 1H-Indole, 3-[6-(4-bromophenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 681809-44-9 CAPLUS

CN Pyrimidine, 4-(1,3-benzodioxol-5-yl)-6-(4-bromophenyl)-2-(1-pyrrolidinyl)- (9CI)  
(CA INDEX NAME)



RN 681809-46-1 CAPLUS

CN 1H-Indole, 3-[6-(4-bromophenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 681809-48-3 CAPLUS

CN Pyrimidine, 4-(1,3-benzodioxol-5-yl)-6-(4-bromophenyl)-2-(1-piperidinyl)-


10/719,896

(9CI) (CA INDEX NAME)



RN 681809-50-7 CAPLUS


CN 1H-Indole, 3-[6-(4-bromophenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:907999 CAPLUS  
DN 141:89052  
TI Polymer-assisted synthesis of ethyl 2-amino-4,6-diarylpyrimidine-5-carboxylates  
AU Vanden Eynde, Jean Jacques; Labuche, Nadege; Van Haverbeke, Yves; Tietze, Lutz  
CS College of Pharmacy, Division of Basic Pharmaceutical Sciences, Xavier University of Louisiana, New Orleans, LA, 70125, USA  
SO ARKIVOC (Gainesville, FL, United States) (2003), (15), 22-28  
CODEN: AGFUAR  
URL: [http://www.arkat-usa.org/ark/journal/2003/General\\_Part\(xv\)/03-805B/805B.pdf](http://www.arkat-usa.org/ark/journal/2003/General_Part(xv)/03-805B/805B.pdf)  
PB Arkat USA Inc.  
DT Journal; (online computer file)  
LA English  
OS CASREACT 141:89052  
IT 714250-73-4P 714250-74-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of amino(diaryl)pyrimidinecarboxylates via substitution of Merrifield resin with thiourea followed by heterocyclization with arylidene(benzoyl)acetates followed by double oxidation and resin cleavage with amines)  
RN 714250-73-4 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4,6-diphenyl-2-(1-pyrrolidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 714250-74-5 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 2-(4-morpholinyl)-4,6-diphenyl-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:375556 CAPLUS  
DN 139:190627  
TI Modification of the structure of 4,6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines: Synthesis and their 5-HT2A receptor activity  
AU Paluchowska, Maria H.; Bojarski, Andrzej J.; Bugno, Ryszard; Charakchieva-Minol, Sijka; Wesolowska, Anna  
CS Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Pol.  
SO Archiv der Pharmazie (Weinheim, Germany) (2003), 336(2), 104-110  
CODEN: ARPMAS; ISSN: 0365-6233  
PB Wiley-VCH Verlag GmbH & Co. KGaA  
DT Journal  
LA English  
OS CASREACT 139:190627  
IT 124959-45-1  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(synthesis of 4,6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines and their 5-HT2A receptor activity)  
RN 124959-45-1 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:615577 CAPLUS

DN 137:169536

TI Preparation of aryl-substituted tetrahydropyrimidines and related compounds as melanocortin-4 receptor binding compounds

IN Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.

PA Millennium Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 228 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062766	A2	20020815	WO 2002-US3566	20020207
	WO 2002062766	A3	20021003		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 6699873	B1	20040302	US 2001-778468	20010207
	EP 1363890	A2	20031126	EP 2002-718920	20020207
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2001-778468	A	20010207		
	US 1999-147288P	P	19990804		
	US 2000-223277P	P	20000803		
	US 2000-632309	A2	20000804		
	WO 2002-US3566	W	20020207		
OS	MARPAT 137:169536				
IT	326481-01-0P, 4-Phenyl-2-piperazin-1-yl-6-p-tolyl-pyrimidine				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)				
RN	326481-01-0 CAPLUS				
CN	Pyrimidine, 4-(4-methylphenyl)-6-phenyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)				





10/719,896

L4 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:115125 CAPLUS

DN 134:178566

TI Preparation of melanocortin-4 receptor binding compounds

IN Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.

PA Millennium Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010842	A2	20010215	WO 2000-US21327	20000804
	WO 2001010842	A3	20010816		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2381008	A1	20010215	CA 2000-2381008	20000804
	EP 1204645	A2	20020515	EP 2000-953837	20000804
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	BR 2000012984	A	20020716	BR 2000-12984	20000804
	JP 2003528810	T	20030930	JP 2001-515309	20000804
	AU 2004202804	A1	20040722	AU 2004-202804	20040624
PRAI	US 1999-147288P	P	19990804		
	US 2000-223277P	P	20000803		
	AU 2000-66216	A3	20000804		
	WO 2000-US21327	W	20000804		


OS MARPAT 134:178566

IT 326481-01-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(target compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)


RN 326481-01-0 CAPLUS

CN Pyrimidine, 4-(4-methylphenyl)-6-phenyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



10/719,896


L4 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2001:42613 CAPLUS  
DN 134:252310  
TI Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including  
Antiasthma Clinical Candidate PNU-142731A  
AU Bundy, Gordon L.; Banitt, Lee S.; Dobrowolski, Paul J.; Palmer, John R.;  
Schwartz, Theresa M.; Zimmermann, David C.; Lipton, Michael F.; Mauragis,  
Michael A.; Veley, Michael F.; Appell, Robert B.; Clouse, Robert C.;  
Daug, Edward D.  
CS Combinatorial and Medicinal Chemistry Chemical Process Research and  
Preparations, Pharmacia, Kalamazoo, MI, 49001, USA  
SO Organic Process Research & Development (2001), 5(2), 144-151  
CODEN: OPRDFK; ISSN: 1083-6160  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 134:252310  
IT 331268-11-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of dipyrrolidinylpyrimidoindoles)  
RN 331268-11-2 CAPLUS  
CN 1H-Benzotriazole, 1-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)- (9CI) (CA  
INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896


L4 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:41253 CAPLUS  
DN 132:207818  
TI A convenient one-pot synthesis of 2-substituted-4,6-diarylpyrimidines  
AU Sharma, P.; Hussain, K. F.; Sukhwai, S.; Kothari, S.; Singhal, M.; Verma, B. L.  
CS Department of Chemistry, Faculty of Science, M L Sukhadia University, Udaipur, 313 002, India  
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(8), 966-968  
CODEN: IJSBDB; ISSN: 0376-4699  
PB National Institute of Science Communication, CSIR  
DT Journal  
LA English  
IT 22539-53-3P 160537-17-7P 160537-18-8P  
160537-19-9P 260445-96-3P 260445-97-4P  
260445-99-6P 260446-01-3P 260446-03-5P  
260446-04-6P 260446-05-7P 260446-06-8P  
260446-07-9P 260446-08-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(one-pot synthesis of 2-substituted-4,6-diarylpyrimidines)  
RN 22539-53-3 CAPLUS  
CN Pyrimidine, 4,6-diphenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 160537-17-7 CAPLUS  
CN Pyrimidine, 4-(4-chlorophenyl)-6-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 160537-18-8 CAPLUS  
CN Pyrimidine, 4-(4-methoxyphenyl)-6-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 160537-19-9 CAPLUS  
CN Pyrimidine, 4,6-bis(4-methoxyphenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)


10/719,896

NAME)




RN 260445-96-3 CAPLUS

CN Morpholine, 4-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 260445-97-4 CAPLUS

CN Morpholine, 4-[4-(4-methoxyphenyl)-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 260445-99-6 CAPLUS


CN Morpholine, 4-[4-(4-chlorophenyl)-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 260446-01-3 CAPLUS


CN Morpholine, 4-[4-(4-methylphenyl)-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896




RN 260446-03-5 CAPLUS

CN Phenol, 2-[2-(4-morpholinyl)-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 260446-04-6 CAPLUS

CN Phenol, 2-[6-(4-methoxyphenyl)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 260446-05-7 CAPLUS


CN Pyrimidine, 4,6-diphenyl-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 260446-06-8 CAPLUS


CN Pyrimidine, 4-(4-methoxyphenyl)-6-phenyl-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 260446-07-9 CAPLUS

CN Pyrimidine, 4,6-bis(4-methoxyphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 260446-08-0 CAPLUS


CN Pyrimidine, 4-(4-chlorophenyl)-6-(4-methoxyphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:809049 CAPLUS  
DN 132:166201  
TI Synthesis, antimicrobial and antifungal activities of some pyrimidine derivatives  
AU El-Gawad, N. M. Abd  
CS Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt  
SO Bulletin of the Faculty of Pharmacy (Cairo University) (1999), 37(2), 47-54  
CODEN: BFPHA8; ISSN: 1110-0931  
PB Cairo University, Faculty of Pharmacy  
DT Journal  
LA English  
OS CASREACT 132:166201  
IT 259086-87-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis, antimicrobial and antifungal activities of some pyrimidine derivs.)  
RN 259086-87-8 CAPLUS  
CN 2,5-Pyrrolidinedione, 1-[4-(2,4-dimethoxyphenyl)-6-(4-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:480549 CAPLUS

DN 131:257520

TI A facile one pot conversion of 3',5'-dibromo-4'-hydroxy substituted chalcones to pyrimidine derivatives and their antibacterial and herbicidal activity

AU Kothari, Seema; Vyas, Rajesh; Verma, B. L.

CS Department of Chemistry, Faculty of Sciences, M. L. Sukhadia University, Udaipur, 313 002, India

SO Indian Journal of Heterocyclic Chemistry (1999), 8(4), 285-288  
CODEN: IJCHEI; ISSN: 0971-1627

PB Prof. R. S. Varma

DT Journal

LA English

IT 245055-69-0P 245055-70-3P 245055-71-4P

245055-72-5P 245055-73-6P 245055-74-7P


245055-75-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antibacterial and herbicidal activity of pyrimidines)


RN 245055-69-0 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-phenyl-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 245055-70-3 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-(4-methoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 245055-71-4 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-(4-methylphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/719,896




RN 245055-72-5 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-(4-chlorophenyl)-2-(1-piperidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 245055-73-6 CAPLUS

CN Phenol, 2,6-dibromo-4-[6-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RN 245055-74-7 CAPLUS


CN Phenol, 2,6-dibromo-4-[6-phenyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]-  
(CA INDEX NAME)



RN 245055-75-8 CAPLUS

10/719,896


CN Phenol, 2,6-dibromo-4-[6-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:149874 CAPLUS  
DN 130:311755  
TI Utilities of 4-(4'-Benzylphenyl)-6-arylpyrimidine-2-thiones for the  
synthesis of biologically active condensed and non-condensed heterocycles  
AU Amine, M. S.  
CS Chemistry Department, Faculty of Science, Zagazig University, Benha, Egypt  
SO Egyptian Journal of Chemistry (1998), 41(1-6), 267-276  
CODEN: EGJCA3; ISSN: 0367-0422  
PB National Information and Documentation Centre  
DT Journal  
LA English  
OS CASREACT 130:311755  
IT 223483-16-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of (benzylphenyl)(aryl)pyrimidinethiones as intermediates for  
biol. active heterocyclic compds.)  
RN 223483-16-7 CAPLUS  
CN Morpholine, 4-[4-phenyl-6-[4-(phenylmethyl)phenyl]-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 42 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:96239 CAPLUS

DN 130:153673

TI Preparation of heterocyclic compounds as antitumor agents

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Watanabe, Tetsuo; Inaba, Masahiro

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9905138	A1	19990204	WO 1998-JP3308	19980724
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2297326	A1	19990204	CA 1998-2297326	19980724
	AU 9883575	A	19990216	AU 1998-83575	19980724
	AU 727013	B2	20001130		
	EP 1020462	A1	20000719	EP 1998-933922	19980724
	EP 1020462	B1	20040211		
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1129597	B	20031203	CN 1998-809385	19980724
	ES 2213286	T3	20040816	ES 1998-933922	19980724
	US 6251900	B1	20010626	US 2000-463214	20000121
PRAI	JP 1997-198804	A	19970724		
	WO 1998-JP3308	W	19980724		


OS MARPAT 130:153673

IT 220229-09-4P 220229-11-8P 220229-17-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of heterocyclic compds. as antitumor agents)

RN 220229-09-4 CAPLUS


CN 1H-Benzimidazole, 1-(2,6-di-4-morpholinyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 220229-11-8 CAPLUS


CN 1H-Benzimidazole, 1,1'-[2-(4-morpholinyl)-4,6-pyrimidinediyl]bis- (9CI)  
(CA INDEX NAME)

10/719,896



RN 220229-17-4 CAPLUS

CN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896


L4 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1998:454205 CAPLUS  
DN 129:189296  
TI Syntheses of thieno[2,3-d]pyrimidines and aminopyrimidines from  
2-alkoxy-5-cyano-4-thioxopyrimidine intermediates  
AU Rehwald, Matthias; Gewald, Karl  
CS Institut of Organic Chemistry, Technical University Dresden, Dresden,  
D-01062, Germany  
SO Heterocycles (1998), 48(6), 1157-1167  
CODEN: HTCYAM; ISSN: 0385-5414  
PB Japan Institute of Heterocyclic Chemistry  
DT Journal  
LA English  
OS CASREACT 129:189296  
IT 211687-29-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of thienopyrimidines and aminopyrimidines via  
alkoxycyanothioxopyrimidines)  
RN 211687-29-5 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 4-phenyl-2,6-di-1-pyrrolidinyl- (9CI) (CA INDEX  
NAME)




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1997:687574 CAPLUS  
DN 128:128  
TI Structure-activity relationship studies of CNS agents. Part 32. Effect of structural modifications in 1-arylpiperazine derivatives on  $\alpha$ 1-adrenoreceptor affinity  
AU Mokrosz, Maria J.; Paluchowska, Maria H.; Charakchieva-Minol, Sijka; Bien, Anna  
CS Institute Pharmacology, Polish Academy Sciences, Krakow, 31343, Pol.  
SO Archiv der Pharmazie (Weinheim, Germany) (1997), 330(6), 177-180  
CODEN: ARPMAS; ISSN: 0365-6233  
PB Wiley-VCH  
DT Journal  
LA English  
IT 171115-27-8P 171115-29-0P 194349-94-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(structural modifications in 1-arylpiperazine derivs. effect on  $\alpha$ 1-adrenoreceptor affinity)  
RN 171115-27-8 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(2-thienyl)-6-(3-thienyl)- (9CI)  
(CA INDEX NAME)




RN 171115-29-0 CAPLUS  
CN Pyrimidine, 4-(2-furanyl)-6-(3-furanyl)-2-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 194349-94-5 CAPLUS  
CN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI) (CA INDEX NAME)

10/719,896





10/719,896

L4 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:468973 CAPLUS

DN 127:185371

TI 4-(3-Furyl)-2-(4-methylpiperazino)pyrimidines: potent 5-HT<sub>2A</sub> receptor antagonists

AU Mokrosz, Maria J.; Duszynska, Beata; Klodzinska, Aleksandra; Deren-Wesolek, Anna; Chojnacka-Wojcik, Ewa; Baranowski, Timothy C.; Abdou, Ibrahim M.; Redmore, Naomi P.; Strekowski, Lucjan

CS Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Krakow, 31-343, Pol.

SO Bioorganic & Medicinal Chemistry Letters (1997), 7(13), 1635-1638  
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier

DT Journal

LA English


IT 124959-45-1 171115-29-0 194349-92-3  
194349-93-4 194349-94-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(furyl(methylpiperazino)pyrimidines as potent behavioral 5-HT<sub>2A</sub> receptor antagonists)


RN 124959-45-1 CAPLUS

CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI) (CA INDEX NAME)



RN 171115-29-0 CAPLUS


CN Pyrimidine, 4-(2-furanyl)-6-(3-furanyl)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 194349-92-3 CAPLUS


CN Pyrimidine, 4,6-di-3-furanyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 194349-93-4 CAPLUS

CN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-(2-thienyl)- (9CI)  
(CA INDEX NAME)



RN 194349-94-5 CAPLUS

CN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI) (CA  
INDEX NAME)



RE.CNT 14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/719,896

L4 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1996:718326 CAPLUS

DN 126:8130

TI Preparation of diarylpyrimidine derivatives as neovascularization inhibitors

IN Konno, Yasuo; Nozaki, Kenji; Yamada, Shozo; Asao, Tetsuji; Suzuki, Takashi; Kimura, Masayasu

PA Taiho Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 77 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9632384	A1	19961017	WO 1996-JP1022	19960412
	W: AU, CA, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2190973	A1	19961017	CA 1996-2190973	19960412
	CA 2190973	C	20010619		
	AU 9652892	A	19961030	AU 1996-52892	19960412
	AU 692090	B2	19980528		
	EP 767170	A1	19970409	EP 1996-909366	19960412
	EP 767170	B1	20021023		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 9603433	A2	19970828	HU 1996-3433	19960412
	JP 3145410	B2	20010312	JP 1996-530893	19960412
	AT 226574	T	20021115	AT 1996-909366	19960412
	US 5786355	A	19980728	US 1996-750197	19961127
	NO 9605334	A	19970212	NO 1996-5334	19961212
	NO 308659	B1	20001009		
PRAI	JP 1995-88284	A	19950413		
	WO 1996-JP1022	W	19960412		
OS	MARPAT 126:8130				
IT	183729-99-9P 183730-00-9P 183730-01-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of diarylpyrimidine derivs. as neovascularization inhibitors)				
RN	183729-99-9 CAPLUS				
CN	Pyrimidine, 2-(1-piperidinyl)-4,6-bis(2,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)				




RN 183730-00-9 CAPLUS

CN Morpholine, 4-[4,6-bis(2,4,5-trimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA


10/719,896

INDEX NAME)




RN 183730-01-0 CAPLUS

CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-bis(2,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1996:565874 CAPLUS  
DN 125:300936  
TI Synthesis and reactions of 6(4)-(p-benzylphenyl)-4(6)-phenylpyrimidine-  
2(1H)-thione  
AU Wasfy, A. A. F.; Amine, M. S.; Eissa, A. M. F.  
CS Chem. Dep., Fac. Sci., Benha Univ., Benha, Egypt  
SO Heterocyclic Communications (1996), 2(4), 375-381  
CODEN: HCOMEX; ISSN: 0793-0283  
PB Freund  
DT Journal  
LA English  
IT 182686-00-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and reactions of (benzylphenyl)phenylpyrimidinethione)  
RN 182686-00-6 CAPLUS  
CN Pyrimidine, 4-phenyl-6-[4-(phenylmethyl)phenyl]-2-(1-piperidinyl)- (9CI)  
(CA INDEX NAME)




10/719,896

L4 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1995:877912 CAPLUS  
DN 124:223  
TI Structure-activity relationship studies of CNS agents. Part 25.  
4,6-Di(heteroaryl)-2-(N-methylpiperazino)pyrimidines as new, potent 5-HT<sub>2A</sub>  
receptor ligands: a verification of the topographic model  
AU Mokrosz, Maria J.; Strekowski, Lucjan; Kozak, Wei Xing; Duszynska, Beata;  
Bojarski, Andrzej J.; Klodzinska, Aleksandra; Czarny, Agnieszka; Cegla,  
Marek T.; Deren-Wesolek, Anna; et al.  
CS Department Medicinal Chemistry, Institute Pharmacology, Polish Academy  
Sciences, Krakow, 31-343, Pol.  
SO Archiv der Pharmazie (Weinheim, Germany) (1995), 328(9), 659-66  
CODEN: ARPMAS; ISSN: 0365-6233  
PB VCH  
DT Journal  
LA English  
IT 171115-26-7P 171115-27-8P 171115-28-9P  
171115-29-0P 171115-30-3P 171115-31-4P  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological  
process); BSU (Biological study, unclassified); PRP (Properties); RCT  
(Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP  
(Preparation); PROC (Process); RACT (Reactant or reagent)  
(structure-activity relationship studies of di(heteroaryl) (N-  
methylpiperazino)pyrimidines as new and potent 5-HT<sub>2A</sub> receptor ligands  
and verification of topog. model)  
RN 171115-26-7 CAPLUS  
CN Pyrimidine, 5-methyl-2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI)  
(CA INDEX NAME)




RN 171115-27-8 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(2-thienyl)-6-(3-thienyl)- (9CI)  
(CA INDEX NAME)

10/719,896




RN 171115-28-9 CAPLUS

CN Pyrimidine, 4-(2-furanyl)-2-(4-methyl-1-piperazinyl)-6-(2-thienyl)- (9CI)  
(CA INDEX NAME)



RN 171115-29-0 CAPLUS


CN Pyrimidine, 4-(2-furanyl)-6-(3-furanyl)-2-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 171115-30-3 CAPLUS


CN Pyrimidine, 4-benzo[b]thien-2-yl-6-(2-furanyl)-2-(4-methyl-1-piperazinyl)-  
(9CI) (CA INDEX NAME)

10/719,896



RN 171115-31-4 CAPLUS

CN Pyrimidine, 4-benzo[b]thien-2-yl-6-(3-furanyl)-2-(4-methyl-1-piperazinyl)-  
(9CI) (CA INDEX NAME)



IT 171115-16-5P 171115-17-6P 171115-18-7P

171115-19-8P 171115-20-1P 171115-21-2P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)


(structure-activity relationship studies of di(heteroaryl)(N-methylpiperazino)pyrimidines as new and potent 5-HT<sub>2A</sub> receptor ligands and verification of topog. model)

RN 171115-16-5 CAPLUS

CN Pyrimidine, 5-methyl-2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl-,  
dihydrochloride, tetrahydrate (9CI) (CA INDEX NAME)




10/719,896



● 4 H<sub>2</sub>O

● 2 HCl

RN 171115-17-6 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(2-thienyl)-6-(3-thienyl)-, dihydrochloride, dihydrate (9CI) (CA INDEX NAME)




● 2 HCl

● 2 H<sub>2</sub>O

RN 171115-18-7 CAPLUS  
CN Pyrimidine, 4-(2-furanyl)-2-(4-methyl-1-piperazinyl)-6-(2-thienyl)-, dihydrochloride, hydrate (2:3) (9CI) (CA INDEX NAME)

10/719,896




● 2 HCl

● 3/2 H<sub>2</sub>O

RN 171115-19-8 CAPLUS

CN Pyrimidine, 4-(2-furanyl)-6-(3-furanyl)-2-(4-methyl-1-piperazinyl)-, dihydrochloride, monohydrate (9CI) (CA INDEX NAME)




● 2 HCl

● H<sub>2</sub>O

RN 171115-20-1 CAPLUS

CN Pyrimidine, 4-benzo[b]thien-2-yl-6-(2-furanyl)-2-(4-methyl-1-piperazinyl)-, dihydrochloride, pentahydrate (9CI) (CA INDEX NAME)

10/719,896




●2 HCl

●5 H<sub>2</sub>O

RN 171115-21-2 CAPLUS

CN Pyrimidine, 4-benzo[b]thien-2-yl-6-(3-furanyl)-2-(4-methyl-1-piperazinyl)-, dihydrochloride, monohydrate (9CI) (CA INDEX NAME)



●2 HCl

● H<sub>2</sub>O


IT 124959-45-1

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(structure-activity relationship studies of di(heteroaryl) (N-methylpiperazino)pyrimidines as new and potent 5-HT<sub>2A</sub> receptor ligands and verification of topog. model)

RN 124959-45-1 CAPLUS

CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI) (CA INDEX NAME)

10/719,896




IT 171115-32-5P 171115-33-6P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(structure-activity relationship studies of di(heteroaryl) (N-methylpiperazino)pyrimidines as new and potent 5-HT<sub>2A</sub> receptor ligands and verification of topog. model)


RN 171115-32-5 CAPLUS

CN Pyrimidine, 4-(2-benzofuranyl)-6-(2-furanyl)-2-(4-methyl-1-piperazinyl)-(9CI) (CA INDEX NAME)



RN 171115-33-6 CAPLUS

CN Pyrimidine, 4-(2-benzofuranyl)-2-(4-methyl-1-piperazinyl)-6-(1-methyl-1H-pyrrol-2-yl)-(9CI) (CA INDEX NAME)



IT 171115-22-3P 171115-23-4P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP


10/719,896 .

(Preparation); PROC (Process)

(structure-activity relationship studies of di(heteroaryl) (N-methylpiperazino)pyrimidines as new and potent 5-HT<sub>2A</sub> receptor ligands and verification of topog. model)

RN 171115-22-3 CAPLUS


CN Pyrimidine, 4-(2-benzofuranyl)-6-(2-furanyl)-2-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 171115-23-4 CAPLUS

CN Pyrimidine, 4-(2-benzofuranyl)-2,6-bis(4-methyl-1-piperazinyl)-, dihydrochloride, monohydrate (9CI) (CA INDEX NAME)



●2 HCl

● H<sub>2</sub>O

10/719,896

L4 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:611675 CAPLUS

DN 123:285884

TI Synthesis and reactions of 2-amino-4-aryl-6-(2'-methoxynaphthyl)pyrimidines

AU Essawy, S. A.; El-Sawy, A. A.; Issac, Y. A.; Ghany, A. M. Abdel

CS Faculty Science, Benha University, Benha, Egypt

SO Egyptian Journal of Chemistry (1994), 37(4), 423-31

CODEN: EGJCA3; ISSN: 0367-0422

PB National Information and Documentation Centre

DT Journal

LA English


IT 169318-91-6P 169318-94-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and reactions of amino(aryl)(methoxynaphthalenyl)pyrimidines)


RN 169318-91-6 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 169318-94-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-(2-methoxy-1-naphthalenyl)-6-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 50 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1995:611674 CAPLUS  
DN 123:256650  
TI Some reactions of 4-(2-methoxynaphthyl)-6-(4-chlorophenyl)pyrimidin-2(1H)-  
one and its corresponding 2-chloro derivative  
AU Essawy, S. A.; Khalil, A. A.; Issac, Y. A.; Ghany, A. M. Abdel  
CS Faculty Science, Benha University, Benha, Egypt  
SO Egyptian Journal of Chemistry (1994), 37(4), 413-21  
CODEN: EGJCA3; ISSN: 0367-0422  
PB National Information and Documentation Centre  
DT Journal  
LA English  
IT 169116-21-6P 169116-22-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 169116-21-6 CAPLUS  
CN Pyrimidine, 4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-(1-  
piperidinyl)- (9CI) (CA INDEX NAME)




RN 169116-22-7 CAPLUS  
CN Morpholine, 4-[4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-  
pyrimidinyl]- (9CI) (CA INDEX NAME)




10/719,896


L4 ANSWER 51 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1995:265581 CAPLUS  
DN 122:105796  
TI A new route to 2-piperidino-4,6-diarylpyrimidines  
AU Sukhwal, Miss Sudha; Verma, Basant L.  
CS College Science, M.L. Sukhadia University, Udaipur, 313 001, India  
SO Indian Journal of Heterocyclic Chemistry (1994), 4(1), 67-8  
CODEN: IJCHEI; ISSN: 0971-1627  
DT Journal  
LA English  
OS CASREACT 122:105796  
IT 22539-53-3P 160537-17-7P 160537-18-8P  
160537-19-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(a new route to piperidinodiarylpyrimidines)  
RN 22539-53-3 CAPLUS  
CN Pyrimidine, 4,6-diphenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 160537-17-7 CAPLUS  
CN Pyrimidine, 4-(4-chlorophenyl)-6-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 160537-18-8 CAPLUS  
CN Pyrimidine, 4-(4-methoxyphenyl)-6-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 160537-19-9 CAPLUS  
CN Pyrimidine, 4,6-bis(4-methoxyphenyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




10/719,896



10/719,896


L4 ANSWER 52 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1995:224473 CAPLUS  
DN 122:23221  
TI Structure-activity relationship studies of CNS agents. Part 14: structural requirements for the 5-HT1A and 5-HT2A receptor selectivity of simple 1-(2-pyrimidinyl)piperazine derivatives  
AU Mokrosz, J. L.; Strekowski, L.; Duszynska, Beata; Harden, D. B.; Mokrosz, Maria J.; Bojarski, A. J.  
CS Inst. Pharmacology, Polish Acad. Sci., Karkow, Pol.  
SO Pharmazie (1994), 49(11), 801-6  
CODEN: PHARAT; ISSN: 0031-7144  
PB Govi-Verlag Pharmazeutischer Verlag  
DT Journal  
LA English  
IT 124959-45-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and structural requirements for 5-HT1A and 5-HT2A receptor selectivity of simple pyrimidinylpiperazine derivs. as CNS agents)  
RN 124959-45-1 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:526585 CAPLUS  
DN 113:126585  
TI Unfused heteropolycyclic compounds as visucides, especially against human immunodeficiency virus  
IN Schinazi, Raymond F.; Strekowski, Lucjan  
PA Georgia State University Foundation, Inc., USA  
SO PCT Int. Appl., 59 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 8911279	A1	19891130	WO 1989-US2104	19890516
	W: AU, JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8937525	A	19891212	AU 1989-37525	19890516
PRAI	US 1988-194293	A	19880516		
	WO 1989-US2104	A	19890516		
OS	MARPAT 113:126585				
IT	124959-45-1 124959-55-3 124959-60-0				
	129224-87-9				
	RL: BIOL (Biological study)				
	(as virucide)				
RN	124959-45-1 CAPLUS				
CN	Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI) (CA INDEX NAME)				




RN 124959-55-3 CAPLUS  
CN Morpholine, 4-(4,6-di-2-thienyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 124959-60-0 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-phenyl-6-(2-thienyl)- (9CI) (CA INDEX NAME)

10/719,896




RN 129224-87-9 CAPLUS

CN Pyrimidine, 4-benzo[b]thien-2-yl-2-(4-methyl-1-piperazinyl)-6-(2-thienyl)-  
(9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:478321 CAPLUS  
DN 113:78321  
TI Chemotherapeutic agents. XVI. Synthesis of pyrimidines and fused  
pyrimidines as leishmanicides  
AU Ram, Vishnu J.  
CS Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226 001, India  
SO Journal fuer Praktische Chemie (Leipzig) (1989), 331(6), 957-63  
CODEN: JPCEAO; ISSN: 0021-8383  
DT Journal  
LA English  
OS CASREACT 113:78321  
IT 128640-86-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 128640-86-8 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 4-(3-methoxyphenyl)-2,6-bis(4-methyl-1-  
piperazinyl)- (9CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 55 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:216844 CAPLUS  
DN 112:216844  
TI Oxidation of (hydroxyamino)- and nitrosopyrimidines. Synthesis of  
substituted 2- and 4-nitropyrimidines  
AU Moskalenko, G. G.; Sedova, V. F.; Mamaev, V. P.  
CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR  
SO Khimiya Geterotsiklicheskikh Soedinenii (1989), (8), 1100-5  
CODEN: KGSSAQ; ISSN: 0453-8234  
DT Journal  
LA Russian  
OS CASREACT 112:216844  
IT 22539-53-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22539-53-3 CAPLUS  
CN Pyrimidine, 4,6-diphenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 56 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:77214 CAPLUS  
DN 112:77214  
TI Preparation of novel diazines as synthetic intermediates for bioactive compounds  
IN Strekowski, Lucjan; Mokrosz, Maria; Harden, Donald B.  
PA Georgia State University Foundation, Inc., USA  
SO PCT Int. Appl., 47 pp.  
CODEN: PIXXD2

DT Patent  
LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 8907599	A2	19890824	WO 1989-US417	19890202
	WO 8907599	A3	19891019		
	W: AU, JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4929726	A	19900529	US 1988-153998	19880209
	AU 8931923	A	19890906	AU 1989-31923	19890202
	US 4963676	A	19901016	US 1989-400502	19890830
	US 5304647	A	19940419	US 1990-572676	19900824
PRAI	US 1988-153998	A	19880209		
	WO 1989-US417	A	19890202		
	US 1989-400502	A3	19890830		
OS	CASREACT 112:77214; MARPAT 112:77214				
IT	124959-55-3P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)				
RN	124959-55-3 CAPLUS				
CN	Morpholine, 4-(4,6-di-2-thienyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)				




IT 124959-45-1P 124959-46-2P 124959-60-0P  
124959-61-1P 124959-66-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for biol. compds.)  
RN 124959-45-1 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl- (9CI) (CA INDEX NAME)

10/719,896




RN 124959-46-2 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4,6-di-2-thienyl-, monohydrobromide  
(9CI) (CA INDEX NAME)




● HBr

RN 124959-60-0 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-phenyl-6-(2-thienyl)- (9CI) (CA  
INDEX NAME)




RN 124959-61-1 CAPLUS  
CN Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-(2-naphthalenyl)-6-(2-thienyl)-  
(9CI) (CA INDEX NAME)



RN 124959-66-6 CAPLUS  
CN Pyrimidine, 4-benzo[b]thien-2-yl-2-(4-methyl-1-piperazinyl)-6-(2-thienyl)-  
, dihydrochloride (9CI) (CA INDEX NAME)




10/719,896




●2 HCl

10/719,896

L4 ANSWER 57 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:507951 CAPLUS  
DN 91:107951  
TI Pyrimidines. 70. Relative reactivity of the chlorine atoms of  
2,2',4-trichloro-4',5-bipyrimidine in the reaction with piperidine  
AU Mikhaleva, M. A.; Naumenko, I. I.; Mamaev, V. P.  
CS Novosibirsk. Inst. Org. Khim., Novosibirsk, USSR  
SO Khimiya Geterotsiklicheskikh Soedinenii (1979), (6), 821-6  
CODEN: KGSSAQ; ISSN: 0453-8234  
DT Journal  
LA Russian  
IT 71224-19-6P 71224-21-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 71224-19-6 CAPLUS  
CN 4,5'-Bipyrimidine, 6-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 71224-21-0 CAPLUS  
CN 4,5'-Bipyrimidine, 6-phenyl-2,2',4'-tri-1-piperidinyl- (9CI) (CA INDEX NAME)



10/719,896


L4 ANSWER 58 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1975:443369 CAPLUS  
DN 83:43369  
TI Pyrimidine derivatives  
IN Narr, Berthold; Roch, Josef; Mueller, Erich; Haarmann, Walter  
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.  
SO Ger. Offen., 121 pp. Addn. to Ger. Offen. 2,430,644.  
CODEN: GWXXBX  
DT Patent  
LA German  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2341925	A1	19750306	DE 1973-2341925	19730820
	AT 7406079	A	19770515	AT 1974-6079	19740724
	AT 340933	B	19780110		
	NO 7402712	A	19750221	NO 1974-2712	19740725
	NO 141163	B	19791015		
	CS 187420	B2	19790131	CS 1974-5405	19740729
	RO 65649	A1	19810830	RO 1974-79722	19740810
	US 3975384	A	19760817	US 1974-497459	19740814
	DD 116831	A5	19751212	DD 1974-180558	19740816
	HU 170230	B	19770428	HU 1974-TO978	19740817
	BE 818990	A1	19750219	BE 1974-147737	19740819
	FI 7402436	A	19750221	FI 1974-2436	19740819
	SE 7410539	A	19750221	SE 1974-10539	19740819
	NL 7411047	A	19750224	NL 1974-11047	19740819
	DK 7404415	A	19750428	DK 1974-4415	19740819
	JP 50049288	A	19750501	JP 1974-94899	19740819
	AU 7472490	A	19760219	AU 1974-72490	19740819
	ZA 7405305	A	19760428	ZA 1974-5305	19740819
	ES 429366	A1	19761016	ES 1974-429366	19740819
	PL 93115	B1	19770530	PL 1974-173567	19740819
	CA 1043789	A1	19781205	CA 1974-207278	19740819
	FR 2241305	A1	19750321	FR 1974-28597	19740820
	GB 1449100	A	19760908	GB 1974-36606	19740820
PRAI	DE 1973-2341925	A	19730820		
	DE 1974-2430644	A	19740626		
IT	56034-57-2				

RL: RCT (Reactant); RACT (Reactant or reagent)  
(oxidation of)

RN 56034-57-2 CAPLUS

CN Thiomorpholine, 4-[6-phenyl-2-(1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 56034-53-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and hydrolysis and decarboxylation of)

RN 56034-53-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-phenyl-6-(4-thiomorpholinyl)-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/719,896




IT 56034-23-2P 56034-54-9P 56034-55-0P  
56034-58-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 56034-23-2 CAPLUS


CN Thiomorpholine, 4-[4-phenyl-6-(1-piperazinyl)-2-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 56034-54-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-(1,1-dioxido-4-thiomorpholinyl)-6-phenyl-  
2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 56034-55-0 CAPLUS

CN Thiomorpholine, 4-[6-phenyl-2-(1-piperazinyl)-4-pyrimidinyl]-, 1-oxide,  
dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

10/719,896


RN 56034-58-3 CAPLUS

CN Thiomorpholine, 4-[6-phenyl-2-(1-piperazinyl)-4-pyrimidinyl]-,  
(2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 56034-57-2

CMF C18 H23 N5 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



10/719,896

L4 ANSWER 59 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1975:140173 CAPLUS

DN 82:140173

TI 2,4,6-Trisubstituted pyrimidines

IN Tani, Hideo; Nakamura, Koji; Mori, Shizuhiro; Yokoo, Nobuo; Kyotani, Yoshitoku; Wada, Yasushi

PA Kowa Co., Ltd.

SO Jpn. Tokkyo Koho, 12 pp.


CODEN: JAXXAD

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49021148	B	19740530	JP 1970-127609	19701228
PRAI	JP 1970-127609		19701228		
IT	54994-18-2P 54994-21-7P 54994-22-8P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	54994-18-2 CAPLUS				
CN	Morpholine, 4,4'-[6-(4-pyridinyl)-2,4-pyrimidinediyl]bis- (9CI) (CA INDEX NAME)				



RN 54994-21-7 CAPLUS


CN Pyrimidine, 4-(4-methyl-1-piperazinyl)-2-(1-piperidinyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-22-8 CAPLUS

CN Morpholine, 4-[4-(4-methyl-1-piperazinyl)-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/719,896



10/719,896

L4 ANSWER 60 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1975:140167 CAPLUS

DN 82:140167

TI Substituted pyrimidines

IN Tani, Hideo; Nakamura, Koji; Mori, Shizuhiko; Yokoo, Nobuo; Kyotani, Yoshitoku; Wada, Yasushi

PA Kowa Co., Ltd.

SO Jpn. Tokkyo Koho, 3 pp.

CODEN: JAXXAD

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 49021149	B	19740530	JP 1970-127610	19701228
PRAI	JP 1970-127610		19701228		
IT	54994-18-2P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antiinflammatory activity of)

RN 54994-18-2 CAPLUS


CN Morpholine, 4,4'-[6-(4-pyridinyl)-2,4-pyrimidinediyl]bis- (9CI) (CA INDEX NAME)






10/719,896

L4 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1969:76976 CAPLUS  
DN 70:76976  
TI Reaction kinetics of substituted 2-chloropyrimidines with piperidine  
AU Mamaev, V. P.; Zagulyaeva, O. A.; Shein, S. M.; Shvets, A. I.; Krivopalov, V. P.  
CS Inst. Org. Chem., Novosibirsk, USSR  
SO Reaktsionnaya Sposobnost Organicheskikh Soedinenii (1968), 5(3), 824-37  
CODEN: RSOTAY; ISSN: 0375-9520  
DT Journal  
LA Russian  
IT 22539-53-3P 22539-54-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22539-53-3 CAPLUS  
CN Pyrimidine, 4,6-diphenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 22539-54-4 CAPLUS  
CN Pyrimidine, 5-methyl-4,6-diphenyl-2-piperidino- (8CI) (CA INDEX NAME)




10/719,896

L4 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1952:27482 CAPLUS  
DN 46:27482  
OREF 46:4675b-e  
TI 2, 4-Diaminopyrimidines. A new series of antimalarials  
AU Falco, E. A.; Goodwin, L. G.; Hitchings, G. H.; Rollo, I. M.; Russell, P.  
B.  
CS Wellcome Research Labs., Tuckahoe, NY  
SO British Journal of Pharmacology and Chemotherapy (1951), 6, 185-200  
CODEN: BJPCAL; ISSN: 0366-0826  
DT Journal  
LA Unavailable  
IT 857428-79-6, Pyrimidine, 2,4-dimorpholino-6-phenyl-  
(antimalarial activity of)  
RN 857428-79-6 CAPLUS  
CN Pyrimidine, 2,4-dimorpholino-6-phenyl- (5CI) (CA INDEX NAME)



10/719,896

L4 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1950:19897 CAPLUS  
DN 44:19897  
OREF 44:3904i,3905a-c  
TI Pyrimidine. IV  
AU Andrisano, Renato  
SO Bollettino Scientifico della Facolta di Chimica Industriale di Bologna  
(1947), Volume Date 1944-1947, 5, 48-51  
CODEN: BSFCAY; ISSN: 0366-3205  
DT Journal  
LA Unavailable  
IT 857428-84-3P, Pyrimidine, 4-(2-furyl)-2,6-dipiperidino-  
RL: PREP (Preparation)  
(preparation of)  
RN 857428-84-3 CAPLUS  
CN Pyrimidine, 4-(2-furyl)-2,6-dipiperidino- (5CI) (CA INDEX NAME)



10/719,896

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

229.47

402.23

STN INTERNATIONAL LOGOFF AT 11:30:14 ON 26 FEB 2007

10/719,896

(1)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal61lbxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 6 NOV 10 CA/Caplus F-Term thesaurus enhanced  
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version  
8.01c now available  
NEWS 8 NOV 20 CA/Caplus to MARPAT accession number crossover limit increased  
to 50,000  
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and  
functionality  
NEWS 13 DEC 18 CA/Caplus pre-1967 chemical substance index entries enhanced  
with preparation role  
NEWS 14 DEC 18 CA/Caplus patent kind codes updated  
NEWS 15 DEC 18 MARPAT to CA/Caplus accession number crossover limit increased  
to 50,000  
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 17 DEC 27 CA/Caplus enhanced with more pre-1907 records  
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 19 JAN 16 CA/Caplus Company Name Thesaurus enhanced and reloaded  
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 22 JAN 22 CA/Caplus updated with revised CAS roles  
NEWS 23 JAN 22 CA/Caplus enhanced with patent applications from India  
NEWS 24 JAN 29 PHAR reloaded with new search and display fields  
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 26 FEB 13 CASREACT coverage to be extended  
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 29 Feb 23 KOREAPAT enhanced with IPC 8 features and functionality  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

10/719,896

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:33:19 ON 26 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:33:32 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10719896RCE.str

10/719,896



chain nodes :

7 8 9 17 24 25 26 27 28 29 30 34 37

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-24 3-37 4-34 5-26 7-8 7-9 17-25 27-29 28-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-24 3-37 4-34 5-26 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 17-25  
27-29 28-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

G4:cy,[\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 24:CLASS 25:Atom 26:Atom  
27:CLASS 28:CLASS 29:CLASS 30:CLASS 34:CLASS 37:CLASS

10/719,896

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:33:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 19007 TO ITERATE

10.5% PROCESSED        2000 ITERATIONS

11 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        371886 TO    388394

PROJECTED ANSWERS:            1477 TO        2703


L2                11 SEA SSS SAM L1

=> d scan



10/719,896

L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Acetamide, N-[4-[[2-(4-hydroxy-1-piperidinyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI)  
MF C25 H22 F3 N5 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

10/719,896


L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-  
pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-,  
ethyl ester (9CI)  
MF C30 H39 N7 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896


L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 4-Piperidinecarboxylic acid, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI)  
MF C26 H25 Cl F4 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896


L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Morpholine, 4-[6-(1,3-benzodioxol-5-yl)-2-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI) .  
MF C25 H25 F3 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-1,4-Diazepine, 1-[(2-chlorophenyl)diphenylmethyl]-4-(2,6-di-1-  
pyrrolidinyl-4-pyrimidinyl)hexahydro- (9CI)  
MF C36 H41 Cl N6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-17-hydroxy-16-methyl-, (16 $\alpha$ )- (9CI)  
MF C38 H52 N6 O3  
CI COM

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- $\alpha,\alpha$ -dimethyl-  
(9CI)


MF C27 H32 Cl F N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 11 ANSWERS REGISTRY: COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-phenyl-2-(4-phenyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI)  
MF C25 H23 N5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




10/719,896

L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-  
[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)


MF C26 H28 F4 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896


L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI)  
MF C19 H20 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1-Piperazinecarboxylic acid, 4-[5-[(4-methoxybenzoyl)oxy]-2,6-di-1-  
pyrrolidinyl-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI)  
MF C29 H40 N6 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/719,896

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY



SESSION

FULL ESTIMATED COST

0.90

1.11

STN INTERNATIONAL LOGOFF AT 09:34:28 ON 26 FEB 2007



chain nodes :

7 8 9 17 24 25 26 27 28 29 30 34

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-24 3-17 4-34 5-26 7-8 7-9 17-25 27-29 28-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-24 3-17 4-34 5-26 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 17-25 27-29 28-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 17:Atom 24:CLASS25:Atom 26:Atom 27:CLASS28:CLASS29:CLASS30:CLASS  
34:CLASS

10/719,896

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS EXPRESS		NOVEMBER 10	CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

10/719,896

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:53:35 ON 26 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:53:45 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10719896RCE2.str



chain nodes :

7 8 9 17 24 25 26 27 28 29 30 34 37

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-24 3-37 4-34 5-26 7-8 7-9 17-25 27-29 28-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-24 3-37 4-34 5-26 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 17-25 27-29 28-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

G4:Gy,[\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom



14:Atom 15:Atom 17:Atom 24:CLASS25:Atom 26:Atom 27:CLAS28:CLAS29:CLASS30:CLASS  
34:CLASS37:CLASS

10/719,896



chain nodes :

7 8 9 17 24 25 26 27 28 29 30 34

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-24 3-17 4-34 5-26 7-8 7-9 17-25 27-29 28-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-24 3-17 4-34 5-26 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 17-25  
27-29 28-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 24:CLASS 25:Atom 26:Atom  
27:CLASS 28:CLASS 29:CLASS 30:CLASS 34:CLASS

L1

STRUCTURE UPLOADED

10/719,896

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:54:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 16311 TO ITERATE

12.3% PROCESSED 2000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 318571 TO 333869


PROJECTED ANSWERS: 1 TO 334

L2 1 SEA SSS SAM L1

=> d scan

10/719,896

L2 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Acetamide, N-[4-[[2-(4-hydroxy-1-piperidinyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- (9CI)  
MF C25 H22 F3 N5 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/719,896

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY





SESSION

FULL ESTIMATED COST

0.45

0.66

STN INTERNATIONAL LOGOFF AT 09:54:29 ON 26 FEB 2007



chain nodes :

7 8 9 22 23 24 25 26 27 31 32 33 34

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-32 4-31 5-23 7-8 7-9 24-26 25-27 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-32 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26 25-27 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,CH2,NH,[\*1]

G2:[\*2],[\*3]

G3:H,OH,COOH,NH2,X,Ak,[\*4],[\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 22:CLASS23:Atom 24:CLASS25:CLASS26:CLASS27:CLASS31:CLASS  
32:Atom 33:CLASS34:CLASS

Generic attributes :

23:

Saturation

: Unsaturated

10/719,896

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that



10/719,896

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:48:37 ON 26 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:48:46 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10719896RCE5.str

10/719,896



chain nodes :

7 8 9 22 23 24 25 26 27 31 32 33 34

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-32 4-31 5-23 7-8 7-9 24-26 25-27 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-32 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26  
25-27 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,CH2,NH, [\*1]

G2:[\*2], [\*3]

G3:H,OH,COOH,NH2,X,Ak, [\*4], [\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 22:CLASS 23:Atom 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 31:CLASS 32:Atom 33:CLASS 34:CLASS

Generic attributes :

23:

Saturation : Unsaturated

10/719,896

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:49:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -     19007 TO ITERATE

10.5% PROCESSED        2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

4 ANSWERS


FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                             BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:        371886 TO    388394  
PROJECTED ANSWERS:            391 TO        1129

L2                4 SEA SSS SAM L1

=> d scan

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI)  
MF C19 H20 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- $\alpha,\alpha$ -dimethyl-  
(9CI)

MF C27 H32 Cl F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

4-ANSWERS RECD: 1007 REC: 01 31  
IN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-  
pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-,  
ethyl ester (9CI)


MF C30 H39 N7 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-  
[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
MF C26 H28 F4 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/719,896

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION


FULL ESTIMATED COST

0.45

0.66

STN INTERNATIONAL LOGOFF AT 10:49:33 ON 26 FEB 2007





chain nodes :

7 8 9 22 23 24 25 26 27 31 32

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-32 4-31 5-23 7-8 7-9 24-26 25-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-32 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26 25-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 22:CLAS23:Atom 24:CLAS25:CLAS26:CLAS27:CLAS31:CLASS 32:Atom

10/719,896

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPplus updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS EXPRESS		NOVEMBER 10	CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

10/719,896

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:58:21 ON 26 FEB 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:58:29 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10719896RCE3.str

10/719,896



chain nodes :

7 8 9 22 23 24 25 26 27 31 32

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-32 4-31 5-23 7-8 7-9 24-26 25-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-32 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26  
25-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 22:CLASS 23:Atom 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 31:CLASS 32:Atom

10/719,896

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:58:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 19007 TO ITERATE

10.5% PROCESSED 2000 ITERATIONS

10 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 371886 TO 388394

PROJECTED ANSWERS: 1316 TO 2484

L2 10 SEA SSS SAM L1


=> d scan

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI)

MF C30 H39 N7 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

10/719,896


L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-  
[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)  
MF C26 H28 F4 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-1,4-Diazepine, 1-[(2-chlorophenyl)diphenylmethyl]-4-(2,6-di-1-  
pyrrolidinyl-4-pyrimidinyl)hexahydro- (9CI)  
MF C36 H41 Cl N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- $\alpha,\alpha$ -dimethyl-  
(9CI)

MF C27 H32 Cl F N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4-Piperidinecarboxylic acid, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-(9CI)


MF C26 H25 Cl F4 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI)  
MF C19 H20 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-17-hydroxy-16-methyl-, (16 $\alpha$ )- (9CI)  
MF C38 H52 N6 O3  
CI COM


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896


L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-phenyl-2-(4-phenyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI)  
MF C25 H23 N5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Morpholine, 4-[6-(1,3-benzodioxol-5-yl)-2-[4-[3-(trifluoromethyl)-2-  
pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI)  
MF C25 H25 F3 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 10 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperazinecarboxylic acid, 4-[5-[(4-methoxybenzoyl)oxy]-2,6-di-1-pyrrolidinyl-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI)

MF C29 H40 N6 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/719,896

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION


FULL ESTIMATED COST

0.45

0.66

STN INTERNATIONAL LOGOFF AT 09:59:13 ON 26 FEB 2007





chain nodes :

7 8 9 22 23 24 25 26 27 31 32 33 35 36 37 38 39 40 45

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-45 4-31 5-23 7-8 7-9 24-26 25-27 32-33 35-36 36-37 37-38 39-40

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-45 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26 25-27 32-33 35-36 36-37 37-38 39-40

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,CH2,NH,[\*1]

G2:[\*2],[\*3]

G3:H,OH,COOH,NH2,X,Ak,[\*4],[\*5]

G4:C,O,S,N

G5:Cy,[\*6],[\*7]



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 22:CLASS23:Atom 24:CLASS25:CLASS26:CLASS27:CLASS31:CLASS  
32:CLASS33:CLASS35:CLASS36:CLASS37:CLASS38:Atom 39:Atom 40:CLASS45:CLASS

Generic attributes :

23:

Saturation : Unsaturated



chain nodes :

7 8 9 22 23 24 25 26 27 31 32

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-32 4-31 5-23 7-8 7-9 24-26 25-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-32 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26 25-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,N,CH2

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 22:CLAS23:Atom 24:CLAS25:CLAS26:CLAS27:CLAS31:CLASS  
32:Atom

Generic attributes :

23:

Saturation

: Unsaturated

10/719,896

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

10/719,896

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:40:54 ON 26 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:41:05 ON 26 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

DICTIONARY FILE UPDATES: 25 FEB 2007 HIGHEST RN 923060-60-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10719896RCE4.str

10/719,896



chain nodes :

7 8 9 22 23 24 25 26 27 31 32

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

1-22 3-32 4-31 5-23 7-8 7-9 24-26 25-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-22 3-32 4-31 5-23 7-8 7-9 10-11 10-15 11-12 12-13 13-14 14-15 24-26 25-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,N,CH2

G2:[\*1],[\*2]

G3:H,OH,COOH,NH2,X,Ak,[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 22:CLASS 23:Atom 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 31:CLASS 32:Atom

Generic attributes :

23:

Saturation : Unsaturated

10/719,896

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:41:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 19007 TO ITERATE

10.5% PROCESSED        2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
                          BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:    371886 TO 388394  
PROJECTED ANSWERS:        687 TO 1593


L2                6 SEA SSS SAM L1

=> d scan



10/719,896

L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-phenyl-2-(4-phenyl-1-piperazinyl)-6-(4-pyridinyl)- (9CI)  
MF C25 H23 N5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

10/719,896

L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinecarboxylic acid, 5-methyl-6-[4-[6-[2-(1-methylethyl)-4-pyridinyl]-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-, ethyl ester (9CI)

MF C30 H39 N7 O2




\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

10/719,896

L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Pyridinemethanol, 5-chloro-6-[4-[6-(4-fluorophenyl)-2-(2-methyl-1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]- $\alpha,\alpha$ -dimethyl-  
(9CI)


MF C27 H32 Cl F N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896


L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 4-(3-furanyl)-2-(4-methyl-1-piperazinyl)-6-phenyl- (9CI)  
MF C19 H20 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Morpholine, 4-[6-(1,3-benzodioxol-5-yl)-2-[4-[3-(trifluoromethyl)-2-  
pyridinyl]-1-piperazinyl]-4-pyrimidinyl]- (9CI)  
MF C25 H25 F3 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/719,896

L2 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(2-methyl-1-pyrrolidinyl)-6-[4-  
[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl] - (9CI)

MF C26 H28 F4 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/719,896

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

0.66

STN INTERNATIONAL LOGOFF AT 10:41:46 ON 26 FEB 2007